Cell Cycle Control, Checkpoint Mechanisms, and Genotoxic Stress

Rodney E. Shackelford,[1] William K. Kaufmann,[2] and Richard S. Paules[1,2]

[1]Growth Control and Cancer Group, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina; [2]Department of Pathology and Laboratory Medicine, and Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

The ability of cells to maintain genomic integrity is vital for cell survival and proliferation. Lack of fidelity in DNA replication and maintenance can result in deleterious mutations leading to cell death or, in multicellular organisms, cancer. The purpose of this review is to discuss the known signal transduction pathways that regulate cell cycle progression and the mechanisms cells employ to insure DNA stability in the face of genotoxic stress. In particular, we focus on mammalian cell cycle checkpoint functions, their role in maintaining DNA stability during the cell cycle following exposure to genotoxic agents, and the gene products that act in checkpoint function signal transduction cascades. Key transitions in the cell cycle are regulated by the activities of various protein kinase complexes composed of cyclin and cyclin-dependent kinase (Cdk) molecules. Surveillance control mechanisms that check to ensure proper completion of early events and cellular integrity before initiation of subsequent events in cell cycle progression are referred to as cell cycle checkpoints and can generate a transient delay that provides the cell more time to repair damage before progressing to the next phase of the cycle. A variety of cellular responses are elicited that function in checkpoint signaling to inhibit cyclin/Cdk activities. These responses include the p53-dependent and p53-independent induction of Cdk inhibitors and the p53-independent inhibitory phosphorylation of Cdk molecules themselves. Eliciting proper G1, S, and G2 checkpoint responses to double-strand DNA breaks requires the function of the *Ataxia telangiectasia* mutated gene product. Several human heritable cancer-prone syndromes known to alter DNA stability have been found to have defects in checkpoint surveillance pathways. Exposures to several common sources of genotoxic stress, including oxidative stress, ionizing radiation, UV radiation, and the genotoxic compound benzo[*a*]pyrene, elicit cell cycle checkpoint responses that show both similarities and differences in their molecular signaling. — *Environ Health Perspect* 107(Suppl 1):5–24 (1999). *http://ehpnet1.niehs.nih.gov/docs/1999/Suppl-1/5-24shackelford/abstract.html*

Key words: *Ataxia telangiectasia*, cancer, carcinogens, Cdk, cell cycle, checkpoints, cyclins, DNA repair, genotoxic stress, ionizing radiation, oxidative damage, p53, pRb, UV

Biology of the Cell Cycle

The development of microscopy in the seventeenth century allowed early microscopists to examine a large number of protozoa, bacteria, molds, animal cells, and other "animalcules" for the first time (*1,2*). With the development of cell theory, and improvements in microscopy and sample preparation in the nineteenth century, the study of cell division became possible. Early examinations of cell division were limited to the observation that cells increased in size from the completion of one cell division or mitosis (M phase) to the initiation of the next. The period between mitoses was termed interphase (*3*). Later, DNA replication was found to occur at a discrete time during interphase, termed DNA synthesis phase or S phase (*4,5*). The period between mitosis and the subsequent S phase was termed Gap 1 (G_1), while the period between S phase and the following mitosis was termed Gap 2 (G_2). Thus the cell cycle was divided into four major phases (*3,6,7*). Cells in a metabolically active state but not progressing to, or through DNA synthesis or cell division, were said to be quiescent or resting (G_0). In the typical dividing eukaryotic cell, G_1 phase lasts approximately 12 hr, S phase 6 to 8 hr, G_2 phase 3 to 6 hr, and mitosis about 30 min, although the exact length of each phase varies with cell type and growth conditions (Figure 1) (*6,8*).

The description of the cell cycle being divided into four phases led to many questions about the regulatory mechanisms cells employ to ensure an ordered and sequential progression from G_1 to M phase, as well as the mechanisms ensuring DNA stability. Some of these questions were summarized as the "completion" and "alternation" problems (*8,9*). In the completion problem, the question is raised as to how cells ensure that specific events are completed before subsequent events are initiated. For example, cells must ensure that once DNA is condensed for segregation during cytokinesis, it remains condensed throughout M phase and does not prematurely decondense. In the alternation problem, the question is raised as to how cells ensure that once an event is completed, it is not inappropriately repeated. For example, cells must ensure that once DNA replication in S phase is completed, it is followed by DNA condensation and not by another round of replication.

Insight into the completion and alternation problems came from cell fusion experiments carried out by Rao and Johnson (*10,11*). When S phase cells were fused to G_1 or G_2 cells, the G_1 cells began premature DNA replication, but the G_2 cells did not re-replicate their DNA. Also when S phase cells were fused with G_1 cells, the resulting cell fusion did not enter M phase until the G_1 nuclei had completed DNA replication. These results indicated that *a*) S phase cells contain an S phase-promoting factor (SPF) activity that is *trans*-dominant acting on G_1 cells but not on G_2 cells, *b*) G_2 cells contain a block that prevents SPF from initiating DNA replication in G_2 cells, and *c*) S phase cells contain a feedback control factor that prevents the initiation of M phase until DNA replication is complete. In other experiments, fusion of M phase cells with G_1, S, or G_2 cells resulted in interphase nuclear membrane breakdown and in chromosome condensation, demonstrating that M phase cells carried a *trans*-dominant M phase-promoting factor (MPF) activity.

Another important question in understanding cell cycle biology deals with the ability of cells to pause transiently during the cell cycle in response to agents that cause damage, particularly to DNA. Surveillance control mechanisms that check to ensure proper completion of early events

Manuscript received at *EHP* 2 October 1998; accepted 25 November 1998.

Address correspondence to R.S. Paules, Growth Control and Cancer Group, MD F1-05, NIEHS, 111 Alexander Dr., PO Box 12233, Research Triangle Park, NC 27709. Telephone: (919) 541-3710. Fax: (919) 541-1460. E-mail: paules@niehs.nih.gov

Abbreviations used: ATM, *Ataxia telangiectasia* mutated; B[*a*]P, benzo[*a*]pyrene; Cdk, cyclin-dependent kinase; IR, ionizing radiation; MMS, methyl methanesulfonate; MNNG, *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine; MPF, mitosis-promoting factor; pRB, retinoblastoma protein; SPF, S phase-promoting factor; UV, ultraviolet.



Figure 1. Schematic representation of Cyc/Cdk protein complexes and the cell cycle.

and cellular integrity before initiation of subsequent events in cell cycle progression are referred to as cell cycle checkpoints and can cause a transient delay that has been suggested to allow the cell more time to repair damage before progressing to the next phase of the cycle [for reviews, see (*12,13*)]. Alternatively, if the damage is too severe to be adequately repaired, the cell may undergo apoptosis or enter an irreversible senescencelike state (*13*).

Molecular Biology of the Cell Cycle

The experiments by Rao and Johnson (*10,11*), although important, did not provide molecular information about the nature of SPF, MPF, or cell cycle checkpoint mechanisms. Since those initial observations, studies in budding and fission yeast, and frog and marine invertebrate oocytes and embryos, *Drosophila* embryos, and mammalian cells have led to the molecular characterization of SPF, and MPF, as well as a greater understanding of the molecular events that govern the cell cycle, the alternation/completion problems, and checkpoint function (*8*). SPF and MPF have now been characterized as protein complexes whose key components consist of a regulatory protein subunit, referred to as a cyclin, and a protein kinase, called a cyclin-dependent kinase (Cdk). Different cyclin/Cdk complexes are expressed in different phases of the cell cycle, with each cyclin having a specific time of appearance and kinase activity [for reviews, see (*8,14–16*)]. In this review we discuss the known cyclin/Cdk activities that characterize each phase of the cell cycle, the cellular signal transduction pathways of cell cycle checkpoints, and several genotoxic insults that can initiate checkpoint function.

Cell Cycle Control

The G_1 Restriction Point

In early G_1, a series of molecular events occur that eventually commit the cell to progression through the cell cycle and division. Early events in the commitment to division include the induction of the D-type cyclins in response to growth factors and subsequent retinoblastoma protein (pRb) phosphorylation by G_1 cyclin/Cdk protein kinase complexes. This later event is necessary for progression through G_1 phase, as described below. In early to mid G_1, the withdrawal of external growth factors can result in a rapid lowering of cyclin D levels and exit of proliferation into a G_0 state (*17*). However, as cells proceed through G_1, a point is reached where the withdrawal of growth factors no longer halts cell cycle progression (*6*). This point is called the restriction point and is thought to coincide with pRb phosphorylation (Figure 1) (*18,19*). The G_1 restriction point has been found to be lost in many human tumors (*20*).

G_1 Cyclins

In mammalian cells, cyclins D and E form active protein kinase complexes with Cdk proteins, which are required for progression of cells through G_1 into S phase. There also is evidence suggesting that cyclin A/Cdk2 complexes may have a role in $G_1 \rightarrow S$ progression, although this is less clear. Cyclin D kinase activity is maximal in early to mid-G_1 (*21*). In G_0 cells, cyclin D levels are low but may be induced by mitogenic stimuli, whereas in continually cycling cell populations, cyclin D protein levels do not significantly oscillate throughout the cell cycle, although there is generally more cyclin D protein in late G_1 (*8,17,21–23*). Cyclin D has a relatively short half-life (~20 min) and rapidly disappears with the removal of mitogenic stimuli or the addition of antiproliferative agents (*17,24,25*). The requirement for cyclin D in regulating the $G_1 \rightarrow S$ transition was demonstrated by the microinjection of antibodies to cyclin D1 and by microinjection of cyclin D1 antisense plasmid into G_1 fibroblasts, both of which resulted in a block of progression into S phase. The same procedures failed to block S phase entry in fibroblasts near the G_1/S border (*26,27*). Overexpression/deregulation of cyclin D has been found in a variety of human tumors, implying that cyclin D can function as a positive growth regulator (*28–30*). In fact, overexpression of cyclin D was found to accelerate G_1 phase in rodent fibroblasts and decrease their dependency on mitogens (*27,31*). However, in cells that constitutively express cyclin D/Cdk4, the assembly of the active kinase complex depends on growth factors (*21*). On the basis of these data, cyclin D is thought to move cells from $G_1 \rightarrow S$ and participate in the transduction of external mitogenic/antiproliferative signals to other components of G_1/S transition cell cycle machinery, thus moving G_0 cells into G_1, and early G_1 cells into the G_1/S transition [(*17,21–25*); for reviews, see (*8,32*)].

Three mammalian isoforms of cyclin D occur (types D1, D2, and D3) and each is differently expressed in different cell types (*22,23,28,33,34*). The D cyclins show some functional redundancy, as cyclin D1 nullizygous mice are viable, although they are smaller than heterozygous or wild-type littermates and exhibit problems in retina and mammary gland development (*35*). Cyclin D2 nullizygous mice are also viable (*36*). However, cyclin D2-deficient females are sterile because of abnormalities in ovarian development, whereas cyclin D2-deficient males display hypoplastic testes. Interestingly, this observation led Sicinski et al. (*36*) to examine human testicular and ovarian tumors for abnormal cyclin D2 expression. Unusually high cyclin D2 mRNA expression was found in some of these tumors. Other differences between the three D-type cyclins have been documented. For example, although cyclin D1 is dysregulated in many tumors, there is little evidence implicating similar dysregulation of cyclins D2 and D3 in tumorigenesis [for review, see (*37*)]. Also, most cell types express cyclin D2 and either D1 or D3, suggesting that cyclins D2 and D1/D3 are not functionally equivalent (*32*).

The D-type cyclins normally associate with Cdk4 and Cdk6 (Figure 1) (*23,38,39*). Like the D-type cyclins, Cdk4 and Cdk6 show some degree of tissue-specific expression and have been found to be amplified-/overexpressed in human tumors and tumor cell lines (*38–44*). The cyclin D/Cdk4–Cdk6 complexes appear to function, at least in part, by phosphorylating the pRb protein (*38,39*). Support for this comes from the observations that in pRb-deficient cells, cyclin D activity is dispensable for passage through the cell cycle (*45*). The pRb and the pRb-related proteins act to suppress progression from $G_1 \rightarrow S$ by sequestering and thereby inactivating a number of regulatory factors [for review, see (*46*)]. Of these factors, the E2F-DP1 transcription factor

families are the best characterized [for reviews, see (*32,47*)]. In G_0 and early G_1 cells, E2F is bound to hypophosphorylated pRb and is inactive. With progression into G_1, the cyclin D/Cdk protein kinase complexes phosphorylate pRb, releasing E2F from pRb. E2F proteins can then form complexes with members of the DP-1 family of proteins and these complexes can act as transcriptional activators for several genes required for S phase. Included among these genes are dihydrofolate reductase, thymidine kinase, histone H2A, DNA polymerase α, proliferating cell nuclear antigen, as well as cyclin E, cyclin A, Cdc2, and E2F1 itself (*45,48–61*). The induction and activation of cyclin D is summarized in Figure 2.

Another cyclin/Cdk complex that plays a crucial role in the G_1/S phase transition is cyclin E/Cdk2. The expression and activity of cyclin E follows that of cyclin D, with increases in cyclin E expression occurring in the nucleus in early G_1, peaking at the G_1/S border (where cyclin E-associated protein kinase activity is maximal), and declining thereafter (Figure 1) (*62–64*). Cyclin E associates with a single Cdk, Cdk2 (*63,65*). Unlike the cyclin D/Cdk4 and cyclin D/Cdk6 complexes that show apparent limited substrate specificity for pRb and related proteins, cyclin E/Cdk2 protein complexes show *in vitro* protein kinase activity toward a number of exogenous protein substrates including pRb and histone H1 (*63,65*). As seen with cyclin D, microinjection of anticyclin E antibody blocks progression of G_1 cells into S, but fails to block cells at the border of G_1/S from proceeding into S phase. Cyclin E differs from cyclin D in that it is required for S phase progression in cells that lack pRb function, demonstrating that it has a function different from that of D-type cyclins (*66*). Similarly, Cdk2 expression has been found to be required for S phase entry, although it was not clear whether this was due to its association with cyclin E and/or cyclin A (*67,68*). Cyclin E dysregulation has been found in human cancers, with amplification of the cyclin E gene common in gastric and colorectal cancers [for review, see (*69*)]. Like cyclin D, overexpression of cyclin E shortens the time cells spend in G_1 (*31,66*).

Lundberg and Weinberg (*70*) have recently demonstrated that cyclin D and E act cooperatively. When either Cdk4/6 or Cdk2 was selectively inhibited, cyclin D/Cdk4-6 complexes where unable to phosphorylate pRb completely. Furthermore, the cyclin E/Cdk2 complex was found to be incapable of phosphorylating pRb unless pRb had previously been partially phosphorylated by a cyclin D/Cdk4-6 complex. Together these observations indicate that pRb inactivation and E2F transcriptional activity require the combined action of at least two distinct cyclin/Cdk complexes. Although cyclin A is believed to function mainly in S and G_2 phase, there is evidence that it can influence G_1 progression as well, since ectopic expression of cyclin A in G_1 cells can cause them to advance prematurely into S phase (*71*).



Figure 2. Schematic representation of cyclin D/Cdk and cyclin E/Cdk protein kinase complexes regulation in the G_0/G_1 transition into S phase.

S Phase Cyclins

DNA replication occurs in a discrete portion of the cell cycle referred to as S phase (*3,6*). Expressed at low levels in G_1, cyclin A protein levels steadily increase from S phase through G_2, with degradation occurring during M phase (*72,73*). Cyclin A activity is thought to contribute to the G_1/S transition, S phase progression, and $G_2 \rightarrow M$ transition. Support for this comes from the observations that microinjection of cyclin A antibody resulted in a failure to replicate DNA in fibroblasts, and that cyclin A null *Drosophila* embryos cannot enter mitosis (*74,75*). In extracts of *Xenopus* eggs, ablation of cyclin A mRNA resulted in the dysregulation of S phase progression and M phase entry (*76*).

Cyclin A associates with two Cdks, Cdk2 and Cdc2 (or Cdk1) (*73,77*). It has been hypothesized that cyclin A/Cdk2 activity is required for S phase progression, whereas cyclin A/Cdc2 activity is required for $G_2 \rightarrow M$ progression. Support for this hypothesis comes from the observation that mouse cells with temperature-sensitive Cdc2 mutations arrest only in G_2, whereas in *Xenopus* cell-free extracts Cdk2 is essential for DNA synthesis (*78,79*). Also, although cyclin A/Cdk2 activity is present in both S and G_2 phase, cyclin A/Cdc2 activity is present only in G_2 (*80*). The endogenous targets of these protein kinases are not known. However, *in vitro* protein substrates for cyclin A/Cdk2 include histone H1 and pRb, and for cyclin A/Cdc2 complexes include histone H1 protein (*72,73,81*). Recently, Knudsen and colleagues (*82*) found that a phosphorylation-site-mutated pRb was capable of blocking progression through S phase, suggesting that the continued hyperphosphorylation of pRb may be a necessary part of cell cycle progression. It is interesting to note that pRb represses both cyclin A and Cdc2 expression, putting these gene products

under G_1 cyclin control (*83,84*). It appears that this repression involves binding of pRb–E2F complexes to and actively repressing transcription from E2F promoters, thus in fact inhibiting gene expression [for review, see (*61*)]. Like cyclins D and E, there is evidence that cyclin A is dysregulated in some human cancers (*85*).

G_2/M Cyclins

$G_2 \rightarrow M$ progression and entry into M phase is regulated by MPF, an activity that is due principally to the protein kinase activity of cyclin B/Cdc2 protein complexes (*86–92*). Cyclin B levels oscillate through the cell cycle, with cyclin B first appearing in S phase, increasing through G_2, and being abruptly degraded at anaphase (Figure 1) (*93*). Cyclin B-associated activity peaks at the G_2/M border and remains until cyclin B degradation (*93*). Three major mammalian cyclin B isoforms have been characterized, cyclin B1, B2, and B3. During interphase, cyclins B1 and B2 are cytoplasmic, whereas cyclin B3 appears to be nuclear (*94–97*). At the G_2/M transition, the cytoplasmic B cyclins translocate to the nucleus prior to nuclear envelope breakdown (*94,95,98–100*). This nuclear translocation appears to be necessary for normal cyclin B activity and is regulated at least in part by phosphorylation (*100*). Cyclin B3 is unusual in that it is nuclear throughout interphase, associates *in vivo* with Cdc2 and Cdk2, and has structural features that resemble cyclin A (*97*). *In vitro*, cyclin B/Cdc2 protein complexes have kinase activity toward a variety of exogenous protein substrates including histone H1 (*92,101*).

Mice have been developed that are nullizygous for either cyclin B1 or B2 (*102*). Mice nullizygous for cyclin B2 developed normally. In contrast, no cyclin B1 homozygous null pups were born, demonstrating that cyclin B1 is an essential gene.

Regulation of Cyclin/Cdk Protein Kinase Activity

Regulation of cyclin/Cdk protein kinase activity during cell cycle progression involves not only regulation of the timing of cyclin protein accumulation and degradation, but also the binding of Cdk inhibitory polypeptides, and phosphorylations and dephosphorylations of both the cyclin proteins and the Cdk's (for reviews, see (*15,103–106*)]. The regulatory consequences of cyclin phosphorylation are not totally clear. Phosphorylation of B-type cyclins appears to influence subcellular localization and activation (*100*). More is known about the regulatory consequences of Cdk phosphorylation. Once complexed with their cyclin subunit, Cdk2 and Cdc2 must be phosphorylated on a regulatory threonine residue (Thr-160 and Thr-161 in humans, respectively) to become active. This activating phosphorylation is accomplished by an activity known as the Cdk-activating kinase, or CAK, which is composed of Cdk7, cyclin H, and a RING-finger protein MAT1 (*107,108*). Cdc2 molecules are phosphorylated on threonine 14 and tyrosine 15 amino acid residues in late S phase and G_2, as they associate with cyclin B molecules. These phosphorylations inhibit the activity of cyclin B/Cdc2 complexes (*109–111*). Thus, these inhibitory phosphorylations appear to be one important mechanism employed by cells to prevent premature activation of cyclin B/Cdc2 complexes before entry into mitosis. Phosphorylations of Cdc2 on Thr-14 and Tyr-15 can be accomplished through the actions of several dual-specificity protein kinases, including Wee1, Mik1, and Myt1 (*112–114*). Thr-14 and Tyr-15 are positioned within the Cdc2 ATP-binding cleft and phosphorylations of these residues are thought to inhibit kinase activity by disrupting the orientation of ATP molecules bound in this cleft (*109,115*). Activation of the cyclin B/Cdc2 complex occurs through dephosphorylation of Thr-14 and Tyr-15 on Cdc2 by the duel-specificity phosphatase Cdc25C (*116–118*). The extremely rapid activation of cyclin B/Cdc2 at the G_2/M border is thought to be brought about by an autocatalytic positive feedback loop involving cyclin B/Cdc2 and Cdc25C (*119*). This occurs when Cdc25C binds to cyclin B/Cdc2, dephosphorylating Cdc2 and activating the protein kinase complex. Cyclin B/Cdc2 in turn phosphorylates Cdc25C, which increases its phosphatase activity, resulting in the activation of more cyclin B/Cdc2 complexes, and in turn resulting in a rapid activation of both the Cdc25C phosphatase and cyclin B/Cdc2. Support for this model comes from the observations that hyperphosphorylation of Cdc25C correlates with increased phosphatase activity (*119,120*).

Regulation of Cell Cycle Checkpoint Function

Under normal circumstances the cell cycle proceeds without interruptions. However, when damage occurs, most normal cells have the capacity to arrest proliferation in G_1, S, and G_2, and then resume proliferation after the damage is repaired. Alternatively, cells may undergo apoptosis with or without growth arrest or enter an irreversible G_0-like state. Cells are acutely sensitive to broken DNA. Even a single double-strand DNA break appears to be sufficient to bring about cell cycle arrest in normal human fibroblasts (*121*). Cellular surveillance pathways that monitor successful completion of early cell cycle events and the integrity of the cell and generate delays in cell cycle progression in response to DNA damage and other events have been given the term checkpoints (*12,13, 122*). Cells exposed to a genotoxic agent while in early G_1 may arrest at a point in mid G_1 phase, whereas those in late G_1 or S phase will slow the initiation of DNA synthesis. Similarly, those exposed to a damaging agent in early to mid G_2 may delay in mid G_2, whereas those in late G_2 or early M phase may delay in mitosis. Thus, checkpoints appear to operate in all phases of the cell cycle. Checkpoint function often involves a delay in activation or inactivation of a particular cyclin/Cdk complex (*122,123*).

The G_1 Checkpoint

Cells exposed to genotoxic agents in early to mid G_1 may delay proliferation in G_1 at the G_1 checkpoint (*124*). G_1 cell cycle arrest in response to DNA damage has been found to depend heavily on the action of the p53 gene product (*125*). p53 has been characterized as a tumor suppressor gene product and is known to be mutated in more than 50% of human cancers (*20*). p53 is normally a short-lived protein, but is induced through posttranscriptional stabilization in response to DNA damage (*125,126*). Agents such as ionizing radiation, radiomimetic chemicals, and UV can all induce p53 (*125–128*). The dependence of the G_1 checkpoint function upon p53 function is demonstrated by the observation that cells containing wild-type p53 alleles undergo a dose-dependent G_1 arrest in response to γ-radiation. However, cells lacking functional p53 alleles enter S phase regardless of dose of γ-radiation (*129*). Similarly, cells from individuals with *Ataxia telangiectasia* (AT) induce p53 poorly in response to ionizing radiation. Not surprisingly, they also exhibit a severely attenuated G_1 checkpoint response after exposure to ionizing radiation (*130*).

Once induced, p53 can function as a transcription regulatory factor, binding to

the regulatory sequences and *trans*-activating a number of genes, including p21, Mdm2, and GADD45 (*131–134*). p53 can also act as a transcriptional repressor by interfering with the binding of basal transcription factors to the TATA motif (*135*). This observation may account for some of the ability of p53 to interfere with neoplastic processes (*135*). p21, also known as Cip1 /Waf1, binds directly to cyclin/Cdk complexes and acts as a Cdk inhibitor, or Cki (*136,137*). p21 can inhibit the kinase activity of cyclin E/Cdk2, cyclin D1/Cdk4, cyclin A/Cdk2, and to lesser extent, cyclin B/Cdc2 (*134,138–140*). Overexpression of p21 can result in G_1 arrest, while p21-deficient murine fibroblasts exhibit a defective G_1 arrest following γ-irradiation (*139,141*). It is important to note however, that p21-deficient fibroblasts exhibit an attenuated G_1 checkpoint, not an ablated one, indicating that other events are required in the G_1 checkpoint (*141*). Interestingly, basal p21 expression is not p53 dependent. Furthermore, p21 expression can be induced in a p53-independent manner under certain conditions such as during cellular differentiation and following serum stimulation and exposure to carbon tetrachloride (*142–145*). Also, p21 is normally associated with active cyclin/Cdk complexes (*146*). It appears that two or more p21 molecules are required per cyclin/Cdk complex to inhibit kinase activity (*147*). p21 is also associated with proliferating nuclear antigen and has been suggested to directly inhibit DNA replication (*148*). However, p21 is not required for inhibition of DNA replication in response to DNA damage in normal human fibroblasts (*149*). The N-terminal half of p21 shares homology with the Cdk inhibitor proteins p27 and p57, and these inhibitors also interact with Cdks in response to other signals (*150,151*).

Another important regulator of the G_1/S cyclin/Cdk complexes is the association of members of the INK4 family of proteins, especially p16, although the role, if any, of the INK4 proteins in cell cycle checkpoint function is not clear. p16 is known to inhibit cyclin D/Cdk4-6 complexes and therefore probably acts as an inhibitor of pRb phosphorylation (*152*). Support for this view comes from the observation that p16 overexpression leads to arrest in G_1 in pRb+/+ cells, but not in pRb–/– cells (*153*). p16-deficient mice develop normally, but show an elevated cancer rate in the presence of carcinogens (*154*). Both somatic and germline p16 mutations have been found in human cancers/familial cancers syndromes, as well as inactivating hypermethylation of the p16 gene in human tumors, demonstrating the importance of p16 as a tumor-suppressor gene [(*155–157*); for review, see (*158*)]. The gene locus encoding p16, INK4a, has recently been found to encode another protein, $p19^{ARF}$, which is produced through splicing of an alternative first exon into an alternative reading frame of the shared second exon. Many p16 mutations arise in the second exon and therefore are also shared mutations in $p19^{ARF}$. Although $p19^{ARF}$ loss has not yet been associated with human tumors, $p19^{ARF}$ null/p16 wild-type mice develop spontaneous tumors at a high rate, indicating that $p19^{ARF}$ functions as a tumor suppressor (*159*). $p19^{ARF}$ has been shown to interact with the MDM2 protein, neutralizing MDM2's inhibitory regulation of p53, resulting in an activation of p53 and, following transient $p19^{ARF}$ expression, may induce a p53-mediated cell cycle arrest in rodent fibroblasts (*160,161*).

Another factor in the G_1 checkpoint is the inhibitory phosphorylation of Cdk proteins on threonine and tyrosine residues, as described above. Phosphorylations and dephosphorylations of G_1 Cdk's are normal components of regulation of G_1 cyclins/Cdk complexes. Specifically, Cdk2 is phosphorylated on Thr-14 and Tyr-15 during the cell cycle (*162,163*). Treatment of cyclin E/Cdk2 and cyclin A/Cdk2 immunoprecipitates with a bacterially expressed Cdc25M2 (the murine homolog of huCDC25 phosphatase) increased the histone H1 kinase activity of these complexes 5- to 10-fold (*163*). Similarly, Cdk4 is phosphorylated on Tyr-17 in response to ultraviolet (UV) treatment and transfection of cells with a mutant Cdk4 that could not be phosphorylated on Tyr-17 resulted in a loss of the UV-induced G_1 checkpoint (*164*). Furthermore, treatment of Daudi Burkitt's lymphoma cells with interferon-α resulted in a G_0-like arrest and rapid elimination of the phosphatase (Cdc25A) required for removal of Cdk2 tyrosine phosphorylation (*165*). Inhibition of the Cdc25A phosphatase by antibody microinjection also resulted in G_1 arrest (*166*). Together these results implicate the regulation of Cdk tyrosine phosphorylation as an important component of regulation of G_1 cyclin/Cdk activity in the G_1 checkpoint response to genotoxic agents.

The S Phase Checkpoint

Less is known about the S phase checkpoint function than the G_1 and G_2 checkpoint functions. Upon exposure to DNA-damaging agents, such as ionizing radiation, mammalian cells exhibit a dose-dependent reduction in DNA synthesis within a few minutes (*167–170*). The suppression is biphasic, with a strong initial suppression at low doses of radiation and less additional suppression at higher dosages. The biphasic response has been attributed to a suppression of radiation-sensitive new replicon initiation followed by the suppression of initiated replicons, the latter being less radiation sensitive (*169,171*). The suppression of replicon initiation is mediated by a *trans*-acting factor, as ionizing radiation inhibits both chromosomal replication and the replication of a resident autonomously replicating plasmid, even when the radiation dosage is not sufficient to damage the autonomously replicating plasmid (*172*). S phase cyclin A/Cdk2 activity, which is thought to be necessary for S phase progression (see previous discussion), is suppressed by treating cells with ionizing radiation. Interestingly, neither the inhibition of DNA synthesis nor the inhibition of cyclin A/Cdk2 activity is seen in cells from patients with AT (*173*). Thus, the AT gene product appears to be required for appropriate S phase checkpoint response to DNA damage.

The G_2 Checkpoint

Ionizing radiation and other agents that trigger the G_2 checkpoint response suppress cyclin B/Cdc2 kinase activation at the G_2/M border (*174,175*). Treatment of mammalian cells with genotoxic agents results in accumulation of $p34^{cdc2}$ molecules that are phosphorylated on amino acid residues Thr-14 and Tyr-15, resulting in inhibition of cyclin B/Cdc2 protein kinase activity (*174–177*). When HeLa cells were transfected with a tetracycline-repressible Cdc2 mutant that could not be phosphorylated on Thr-14/Tyr-15, the G_2 checkpoint was partially ablated, indicating that these phosphorylations are an important inhibitory component of the G_2 checkpoint (*178*). As mentioned previously, activation of the cyclin B/Cdc2 complex occurs through Cdc2 dephosphorylation on Thr-14/Tyr-15 by the duel-specificity protein phosphatase Cdc25C (*116–118*). Hyperphosphorylation of Cdc25C correlates with increased Cdc25 protein phosphatase activity (*119,120*), and in DNA-damaged cells, Cdc25C does not reach its hyperphosphorylated state (*179*). In addition, although cyclin B/Cdc2-Cdc25C association normally occurs at the G_2/M border, this interaction

does not occur in cells arrested in G_2 by DNA damage (*179*).

This interaction might be prevented through the action of the Chk1 kinase. This kinase phosphorylates Cdc25C on Ser216, leading to its binding by 14-3-3 proteins and apparent sequestration from its physiologic substrate, the cyclin B/Cdc2 protein complex (*180,181*). When a nonphosphorylatable Cdc25C mutant (Ser216→Ala216) was expressed in HeLa cells, the cells escaped radiation-induced G_2 checkpoint delay [(*180*); for review, see (*182*)]. As with their G_1 and S phase checkpoint function, cells from individuals with AT have defective G_2 checkpoint function (*173,176,183–186*). It has been speculated that the AT gene product may function as an upstream regulator of Chk1 (Figure 3) (*182*).

An additional component that likely contributes to the G_2 checkpoint is regulation of the subcellular localization of cyclin B/Cdc2 protein complexes. Cyclin B/Cdc2 complexes accumulate in the cytoplasm in S/G_2 phase and then as cells progress from G2→M, cyclin B/Cdc2 complexes move into the nucleus (*94,95*). Cyclin B complexes are retained in the cytoplasm in response to ionizing radiation treatment, suggesting that differential localization might also account for some aspects of the G_2 checkpoint function (*187–189*).

Another mechanism of suppression of cyclin B/Cdc2 protein kinase activity may involve the regulation of cyclin B levels. In S phase-irradiated cells, cyclin B mRNA and protein levels have been reported to be inhibited, whereas in G_2-irradiated cells, cyclin B mRNA stability and promoter activity are suppressed (*190–192*). It is important to note, however, that cyclin B downregulation has not been observed in other studies (*176,193–197*), and the importance of this level of regulation remains unclear.

The Cdk inhibitor p21 has been shown to associate with the cyclin B/Cdc2 complex. Cells in which the function of p53 has been disrupted either by expression of SV40 T-antigen or expression of the human papilloma virus type 16 E6 gene product (both of which bind and functionally inactivate p53, and hence prevent p53-dependent induction of p21 expression) have been found to have an accelerated G_2 entry and higher cyclin A/B kinase activity (*140,198–202*). In fact, it has been suggested that p21 plays a role in the G_2/M transition by inhibiting the activation of cyclin A/Cdk2 kinase complexes, thus delaying the activation of cyclin B/Cdc2 complexes in G_2 and that this delay could contribute to G_2 checkpoint function (*140*). However, normal human fibroblasts expressing the E6 protein for only a few population doublings show a normal initial G_2 checkpoint response to ionizing radiation, suggesting that p21 is not required for the immediate G_2 checkpoint in response to ionizing radiation (*203*). Thus the role of p21 appears to be ancillary for the immediate early G_2 checkpoint delay.



Figure 3. A schematic representation of the known or suggested interactions of proteins in the G_2 checkpoint signal transduction response to double-strand DNA breaks.

The Spindle Checkpoint

Most cells contain a spindle checkpoint that arrests cells in mitosis until all chromosomes are attached properly to the spindle [for reviews, see (*204–206*)]. Much of our understanding of the genes and the gene products that make up the spindle checkpoint pathway comes from studies with budding yeast and frog eggs, in addition to studies with mammalian systems. The critical transition from metaphase to anaphase and the separation of sister chromatids is monitored by the spindle checkpoint gene products that include the Mad (mitotic arrest defective) proteins, Mad1-3p, the Bub (budding uninhibited by benomyl) proteins, Bub1-3p, and Mps1 (*206*). To progress through this transition, cells must proteolytically degrade a number of proteins that are required earlier for entry into mitosis and this is accomplished by the activation of the proteasome, a component of the large multiprotein complex referred to as the anaphase-promoting complex or APC (*207–209*). Ubiquitin conjugation and proteolysis by APC results in the degradation of cyclin B proteins and the inactivation of MPF that is necessary for exit from mitosis (*210,211*) as well as the degradation of proteins involved in sister chromatid cohesion such as Pds1p (*212,213*) and proteins involved in cross-linking spindle microtubules such as Ase1p (*214*). Agents such as nocodazole and colcemid arrest cells in a prometaphase state because of disruption of microtubule reorganization and spindle apparatus formation (*215,216*). Anaphase will not begin until all the kinetochores receive bipolar spindle apparatus attachments (*217*). Li and Nicklas (*218*) showed that an M phase block induced by an unattached chromosome in insect cells was relieved through the application of tension to the unattached chromosome. It was hypothesized that tension resulted in a change in kinetochore chemistry, relieving the M phase arrest. Furthermore DNA-damaging agents, in addition to spindle-damaging agents, can activate the spindle checkpoint surveillance mechanism and this signaling pathway seems to involve Cdc20 proteins that interact with the Mad proteins (*219,220*), Mec1 proteins, which signal through Psd1p (*213*), the Polo-like kinase

(Plk) proteins (*221–224*), and perhaps protein kinase A (PK A), which can regulate the activity of APC (*225*). As with the other checkpoint functions, the spindle checkpoint is disrupted in tumor cells, with both a reduction in the levels of hsMAD2 observed in breast cancer cells (*226*) and mutationally inactive BUB1 found in tumor cells displaying chromosomal instability (*227*).

p53 and pRb were implicated as having roles in the spindle checkpoint response on the basis of the observation that cells lacking either function when cultured in the presence of spindle-damaging agents inappropriately initiate DNA synthesis without undergoing cytokinesis (*228,229*). However, recent evidence indicates that p53 and pRb probably do not function in this checkpoint (*230,231*). In fact,cells that were either wild type or deficient for either p53 or pRb all transiently arrested in M phase in response to nocodazole treatment. After roughly 24 hr all four cell types entered a G_1-like state with an interphase nuclear structure but with a 4N DNA content (a process referred to as adaptation or restitution). However, the p53- and pRb-deficient cells went on to rereplicate their DNA, becoming 8N and higher. These results were interpreted to indicate that cells undergoing the adaptation or restitution process in the continued presence of nocodazole suffered genomic damage that was recognized by the p53-dependent and pRb-dependent G_1 checkpoint surveillance system that monitors genomic integrity and regulates entry into the DNA replicative cycle.

Checkpoint Signaling, Caffeine, and DNA Repair

Checkpoint signaling has been hypothesized to give the cell time to repair broken DNA, or alternatively, to induce a program of either replicative senescence or apoptosis (*8,12,13,121*). On the basis of this hypothesis, suppression of the checkpoint response should result in decreased cell viability. Certain drugs such as the methylxanthines, e.g., caffeine and pentoxifylline, are capable of relieving the G_1, S, and G_2 checkpoint delay periods (*232–238*). When cells are treated simultaneously with these drugs and DNA-damaging agents such as ionizing radiation or alkylating agents, the lethality of the DNA-damaging agent is potentiated (*239–243*). For example, when baby hamster kidney cells synchronized at G_1/S were treated with 0.5 μM nitrogen mustard, 90% survived. However, in the presence of 2 mM caffeine, the same treatment resulted in 5- to 10-fold greater lethality (*244*). The molecular mechanism of caffeine's action remains unclear, but one of the consequences of the abrogation of the induction of the G_1 delay following DNA damage is a failure to induce p53, and hence p21 (*125*). More recently caffeine has been found to inhibit the G_2 checkpoint function by increasing Thr-14/Tyr-15 dephosphorylation on Cdc2 (*197*). The finding that overriding the G_1 and G_2 checkpoints results in lowered cell viability after damage supports the theory that one function of these checkpoints is to allow cells time to stop to repair damage before continuing the cell cycle.

Heritable Human Cancer Syndromes and the Cell Cycle

The molecular defects present in a number of heritable human cancer-prone syndromes have been characterized. Not surprisingly, these defects often compromise the ability of the cell to checkpoint delay in response to DNA damage and/or the ability to repair damaged DNA. Next, we briefly discuss the molecular defects in several heritable human cancer-prone syndromes and their effect on human health.

Ataxia telangiectasia and pATM

Ataxia telangiectasia is an autosomal recessive disease characterized by premature aging, sensitivity to ionizing radiation, sterility, immune dysfunction, acute cancer predisposition, telangiectasias, and progressive ataxia and neuronal degeneration, particularly of the Purkinje cells of the cerebellum (*245–247*). AT heterozygotes are reported to have elevated cancer risk, particularly of developing lymphoproliferative disease and breast cancer (*248–250*). In culture, fibroblasts from patients with AT exhibit premature senescence, increased serum requirements, increased chromosomal instability compared to that of normal human fibroblasts, abnormally rapid telomere shortening, and sensitivity to ionizing radiation and radiomimetic chemicals (*169,251–254*). Recently the gene mutated in AT (AT mutated or *ATM*) was identified (*255,256*). The *ATM* gene product (pATM) has been hypothesized to be a sensor of DNA strand breaks and to be required in the DNA damage response signal transduction pathway that results in the activation of p53 in response to DNA strand breaks (*121,128*). Recently, the protein product of the *ATM* gene was demonstrated to have protein kinase activity that is activated in response to IR but not UV exposure and that is capable of phosphorylating p53 on serine residue 15 (*257,258*). In addition, pATM has been suggested to be a cellular sensor of oxidative stress, making pATM null cells abnormally sensitive to oxidative stress from such sources as ionizing radiation and H_2O_2 [for review, see (*259*)].

Cells in culture from individuals with AT exhibit severely impaired G_1, S, and G_2 checkpoint functions (*170,183,186*). The defect in the G_1 checkpoint in AT cells has been found to be associated with a defect in the induction of p53 protein in response to IR exposures, with an induction that is only slight and occurs with delayed kinetics (*133,260,261*). Interestingly, however, AT cells induce p53 in response to UV exposures (*260,261*). AT cells exposed to IR during S phase show little inhibition of DNA synthesis (i.e., radioresistant DNA synthesis) or inhibition of cyclin A/Cdk2 activity (*170, 172,173,262–264*). AT cells have been found to lack a normal G_2 checkpoint response to IR exposure (*176,183–186*). The exact molecular defect in response to DNA damage in cells from individuals with AT remains to be elucidated. AT cells have shown apparently normal repair of single-strand DNA (ssDNA) breaks and show global double-strand DNA (dsDNA) break repair that appears to have the same kinetics as normal cells (*265–267*). However, evidence supports the interpretation that AT cells are defective in certain types of dsDNA break repair. Initial indication of an inability to repair dsDNA breaks was the observation of increased chromosomal aberrations, in particular both chromatid and total breaks, in AT cells following exposures to DNA-damaging agents and especially exposures in G_2 phase (*252,268–273*). Thus, the molecular defect in AT cells may be an inability to respond correctly to certain types of dsDNA breaks, particularly those arising from reactive oxygen species/oxidative stress [for review, see (*13*); (*274,275*)]. Evidence supporting the involvement of pATM in sensing oxidative stress comes from the observations that pATM null cells resynthesize glutathione unusually slowly after depletion with diethylmaleate and are abnormally sensitive to the damaging effects of hydrogen peroxide, superoxide, and nitric oxide (*267,276–279*). Whatever the exact nature of the defect in pATM function, the inability of AT cells to initiate the checkpoint function in

response to ionizing radiation clearly demonstrates how the ablation of one gene product involved in checkpoint function and maintenance of genomic integrity results in lowered cellular viability and greatly enhanced predisposition to cancer.

Retinoblastoma and pRb

Retinoblastoma (Rb) is a childhood retinal tumor that occurs in approximately 1 in 20,000 births worldwide, which is roughly 3% of all pediatric malignancies. All bilateral and some unilateral Rb cases (approximately 40%) are genetically determined and appear by the age of 15 months. Sporadic Rb (60% of Rb cases) is mainly unilateral, with diagnosis occurring later at 2 to 3 years of age. Analysis by Knudson demonstrated that bilateral (genetic) Rb resulted from a single somatic gene mutation. Analysis of most unilateral Rb cases, however, followed second-order kinetics, indicating that tumor formation required two mutational events. (*280,281*). Individuals with hereditary Rb who survive the Rb tumor are at high risk for later developing a second primary cancer, particularly osteosarcoma (*282*). The *Rb* gene is altered in a variety of human cancers, including breast, lung, and bladder cancers (*283–289*). Relatives of Rb patients often have elevated cancer rates (*290*).

Rb null mice die at day 14 to 16 in embryogenesis, exhibiting neuronal cell death and defective erythropoiesis (*291*). Heterozygous mice with one defective *Rb* allele do not develop retinoblastomas but develop pituitary adenomas in which the wild-type *Rb* gene is lost (*292,293*). The *Rb* gene product appears to play a role in the maintenance of genomic stability (*294,295*). Both White et al. (*294*) and Reznikoff et al. (*296*) introduced human papilloma virus type 16 E6 proteins (which inactivate p53) and E7 proteins (which inactivate pRb) into isogenic human cells and, after extensive passaging, found that although the E6-transformed cells showed significant chromosomal abnormalities, the E7-transformed cells had minimal alterations. However, cells lacking functional pRb were found to amplify the dihydrofolate reductase gene when grown in the presence of methotrexate, indicating that loss of pRb function can contribute in some degree to genetic instability (*294,295*). These data, together with the data on germline *Rb* mutation, demonstrate that the *Rb* gene product plays a significant role in the maintenance of genomic integrity.

Li-Fraumeni Syndrome and p53

Li-Fraumeni syndrome (LFS) is a rare heritable disease characterized by soft tissue sarcomas in children and young adults, early development of breast cancer in close relatives, and high rates of leukemia, brain, and adrenocortical tumors, osteosarcomas, and a number of other neoplasms (*297–300*). LFS shows an autosomal dominant transmission pattern and involves a germline mutation of *p53* (*301,302*). Interestingly, examinations of all 11 exons, the splice junctions, and the promoter regions of the *p53* gene in LFS families has shown that roughly 30% of LFS families do not show *p53* coding region mutations (*303*). The nature of the molecular defect in these families remains unknown.

Studies of cells that lack wild-type p53 function have demonstrated that lack of p53 can result in persistent chromatid damage after exposure to IR, changes in cell cycle checkpoint delay initiated by IR in G_1 phase, dysregulation of apoptosis, increased spontaneous immortalization, and chromosomal instability with long-term growth in culture, even in the absence of DNA-damaging agents (*125,176,201,304–310*). Loss of the wild-type *p53* allele in LFS cells results in abrogation of the G_1 checkpoint. Reintroduction of wild-type *p53* can restore the G_1 checkpoint and genomic stability (*307*). *p53* null mice develop normally, although 75% develop tumors by 6 months of age, usually lymphomas with some sarcomas (*311*). In contrast, mice with a single null *p53* allele had a delayed onset of spontaneous tumors, with osteosarcomas and soft tissue sarcomas predominating (*311*). These mice were also more susceptible to the effects of carcinogens than p53 wild-type mice (*312*). p53 null mice were abnormally sensitive to the effects of IR (*313*). It is interesting to note that some p53 mutations have a *trans*-dominant effect, partially inhibiting the action of the remaining wild-type p53 protein (*305, 314–319*). The tendency toward genomic instability, tumorigenesis, and loss of checkpoint function in LFS cells and p53-deficient transgenic mice, is a good example of how impaired p53 function can have profound effects on cell cycle regulation and cancer development.

Environmental Sources of Genotoxic Stress

Humans come into daily contact with an enormous number of DNA-damaging agents. Therefore, it is not surprising that elaborate molecular regulatory systems exist to maintain cellular genomic integrity. Genotoxic substances may come from both endogenous and exogenous sources. Some of these sources commonly encountered are discussed below.

Ultraviolet Radiation

Exposure to UV light induces a number of cellular changes, including the generation of DNA lesions, the induction of stress proteins (such as p53 and p21), and the initiation of cell cycle checkpoint arrest in cycling cells (*126,127,320–331*). UV radiation is divided into three classes based on wavelengths; UV-A (400–320 nm), UV-B (320–290 nm), and UV-C (290–100 nm). UV-A and UV-B are more biologically relevant, as UV-C is mostly absorbed in the upper atmosphere by ozone (*324*). The main direct UV-induced DNA lesion is the cross-linking of adjacent pyrimidines through formation of a cyclobutane-like four-membered ring structure with saturation of the 5,6 double bonds, referred to as a pyrimidine dimer (*320–322,328–330*). The formation of pyrimidine dimers is a UV-reversible process; however, equilibrium lies far to the right and favors the formation of dimers (*330*):

$$Py + Py \Leftrightarrow Py <> Py$$

Thymine–thymine dimers are the most common pyrimidine dimers formed following UV exposures, with cytosine–cytosine and cytosine–thymine dimers also occurring (*330*). However, most UV-induced mutations occur at cytosines, suggesting that cells are able to replicate DNA through thymine dimer lesions without error (*332,333*). UV radiation also produces a number of less common DNA lesions such as the mutagenic 6–4 pyrimidine–pyrimidone dimers, thymine glycols, and protein–DNA cross-linking (*330*). UV radiation also generates DNA damage indirectly via through the production of reactive oxygen species (ROS), including superoxide ($O_2^{\cdot -}$), the hydroxyl radical ($^{\bullet}OH$), and hydrogen peroxide (H_2O_2), all of which rapidly react with each other and surrounding biomolecules. In addition, exposure to UV radiation can cause multimerization, clustering, and activation of cell surface receptor proteins for growth factors and cytokines, with activation of receptor-associated tyrosine kinase activities (*334*). Lastly, UV exposure elicits a number of other events that can lead to DNA damage and the promotion of tumor growth. Among these events are the induction of gene expression and/or activity such

as c-*fos* and protein kinase C (*335,336*), recruitment of inflammatory cells (with the accompanying release of ROS), the production of cytokines, and immunosuppression [for review, see (*337*)].

Exposure to UV radiation is associated with an increased skin cancer risk and premature aging of the skin, particularly among fair-skinned individuals with histories of being sunburned. A strong positive correlation also exists between skin cancer and proximity to the equator, indicating that higher UV doses to human populations result in higher incidences of skin cancer [for reviews, see (*338–342*)]. Enhanced removal of UV-induced pyrimidine dimers lowers skin cancer rates in mice, indicating that unrepaired dimers cause cancer in mammalian skin (*343*). Individuals with the heritable syndrome *Xeroderma pigmentosum* (XP) have impaired ability to remove DNA lesions induced by UV and consequentially are extremely sensitive to UV exposure, which results in an increased risk of developing skin cancers (*344–357*). Generation of mice deficient in *XP* genes have confirmed the important role these gene products play in protecting against UV-induced tumorigenesis (*358–360*). Skin cancer is the most prevalent malignancy in the United States, indicating that the genotoxic effects of UV radiation are a significant health hazard (*342*).

Ionizing Radiation

Ionizing radiation was first demonstrated to be mutagenic by Muller in 1927 (*361*). Since that time, IR has been demonstrated to induce mutations and cause cancer in a dose-dependent manner (*362–368*) [for review, see (*369*)]. IR damages all components of the cell and is known to produce more than 100 distinct DNA adducts (*365*). Data derived from studies on the survivors of the Hiroshima and Nagasaki bombings indicate that exposures to IR resulted in an increased cancer incidence over that in unexposed populations, with increases observed in incidences of leukemia, and breast, stomach, colon, and lung cancers (*370*). These studies also demonstrated that prenatal exposure to IR can also cause mental retardation and microcephaly (*371,372*).

IR damages DNA through direct and indirect mechanisms. Direct damage to DNA occurs as a result of the interaction of radiation energy with DNA. This can result in the generation of a variety of lesions, including the generation of abasic deoxyribose sites in DNA that are produced as a consequence of destabilization of the *N*-glycosidic bond, generation of ssDNA breaks and generation of dsDNA breaks. Indirect DNA damage comes from the interaction of DNA with reactive species formed by IR (*367,373–375*). Water is the predominant cellular constituent and more than 80% of the energy in IR deposited in cells results in the ejection of electrons from water (*376,377*). Subsequent reactions following this event can result in the formation of reactive oxygen species such as superoxide ($O_2^{\cdot-}$), the hydroxyl radical ($^{\cdot}OH$), e^-, $H^{\cdot}$, H_2, and H_2O_2.

Exposure to IR is a potent inducer of cell cycle checkpoint responses, resulting in p53 protein induction and Thr-14/Tyr-15 phosphorylation of Cdks. Environmental sources of IR include natural background radiation, medical procedures such as X-rays, radon, and in some areas such as those effected by the Chernobyl accident, environmental contamination (*378–381*).

Reactive Oxygen Species

Although oxygen is an absolute requirement for the survival of most metazoans, it can damage biologic molecules, including DNA. Normal cellular metabolism, as well as the metabolism of a variety of xenobiotics, produces an array of ROS that are highly reactive and can readily damage DNA. Under conditions of oxidative stress, cycling cells will exhibit cell cycle checkpoint responses (*382–384*). ROS have been implicated as important factors in a large number of biologic events including aging, carcinogenesis, atherosclerosis, strokes, and autoimmune disorders [for reviews, see (*385–390*). Ames and Shigenaga (*388*) have estimated that roughly 2×10^4 lesions occur per day per human genome because of oxidative damage to DNA. The number of different modifications resulting from ROS acting on DNA include both ssDNA and dsDNA breaks, DNA–protein cross-links, and a wide variety of base and sugar modifications (*391*). The number of ROS from both endogenous and exogenous sources that have been proposed to damage DNA is large. Here we focus on several thought to have important affects on biologic processes.

Hydrogen Peroxide/Hydroxyl Radical. H_2O_2 is produced by a wide variety of intracellular events, particularly in normal oxidative electron transport in the mitochondria, and it is normally present in most cells at a concentration of about 10^{-8} M (*392*). H_2O_2 participates in DNA damage through a variety of pathways including the production of $^{\cdot}OH$ through such reactions as the Fenton reaction (*393,394*):

$$Fe^{2+} + H_2O_2 \rightarrow {}^{\cdot}OH + {}^{\cdot}OH + Fe^{3+}$$

$^{\cdot}OH$ is an extremely strong oxidant, with a redox potential of approximately +1.35 V, making it capable of degrading most biologic molecules, including DNA (*367,373,395,396*). The number of different DNA modifications that $^{\cdot}OH$ is capable of producing appears to be over 100 (*365*). $^{\cdot}OH$ has been implicated in the etiology of human cancers such as breast cancer and leukemia (*397,398*). In addition to being produced from endogenous sources, $^{\cdot}OH$ can be generated in the human body after exposures to a variety of exogenous substances including cigarette tars, dietary components high in fat and low in plant fiber, ethyl alcohol, asbestos fibers, and IR (*365,399–402*).

Superoxide. Though less reactive than other ROS such as $^{\cdot}OH$, $O_2^{\cdot-}$ can damage biomolecules, including DNA. Approximately 2% of the oxygen consumed by human cells is converted to $O_2^{\cdot-}$, resulting in a steady concentration of $O_2^{\cdot-}$ within human cells of 1.0×10^{-11} M, this in turn resulting in the generation of an estimated 10,000 DNA lesions per genome per day (*403–405*). Like H_2O_2, $O_2^{\cdot-}$-induced damage is thought to be due mainly to conversion to $^{\cdot}OH$ by such pathways as the Haber-Weiss reaction (*406*):

$$H_2O_2 + O_2^{\cdot-} \rightarrow {}^{\cdot}OH + OH^- + O_2$$

Like H_2O_2-induced damage, much of the $O_2^{\cdot-}$ found within cells is produced from the mitochondrial electron transport chain (*407*). $O_2^{\cdot-}$ is detoxified by conversion to H_2O_2 through the action of superoxide dismutase, which in turn is converted into $H_2O + O_2$ by the action of catalyze (*404*). The toxicity of $O_2^{\cdot-}$ is illustrated by the neurodegeneration seen in Lou Gehrig's disease (in which superoxide dismutase levels are low) and by the recent observation that overexpression of human superoxide dismutase in the motor neurons of *Drosophila* resulted in a 40% increase in lifespan (*404,408*).

Nitric Oxide. $^{\cdot}NO$ is an important proinflammatory mediator produced constitutively by vascular endothelial cells, some neuronal cell types, and activated macrophages (*409*). $^{\cdot}NO$ appears to damage DNA by combining with $O_2^{\cdot-}$ and forming the peroxynitrite radical. The

peroxynitrite radical is a similar to •OH and can readily damage biomolecules (*410*). •NO and cigarette tar synergistically induce DNA breakage, suggesting that •NO might react with many exogenous compounds to produce genotoxic substances (*411*).

Genotoxic Chemicals

Within the environment are an enormous number of both natural and man-made substances that have genotoxic properties. Most of these substances are chemical compounds that have the capacity to covalently modify DNA molecules. Within this category are such compounds as cisplatin and nitrogen mustard, which have been shown to generate strong cell cycle checkpoint responses to DNA damage generated following exposures (*179,412–416*). Also in this class are compounds such as methyl methanesulfonate (MMS) and *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine (MNNG) that transfer methyl or ethyl groups to DNA bases. Exposure to methylating agents has been reported to result in cell cycle checkpoint delays, particularly in cells defective in certain aspects of DNA repair (*417–419*). Polycyclic aromatic hydrocarbons (PAHs) comprise a family of compounds that modify DNA with bulky lesions and, because of their prevalence in the environment, pose a significant human health hazard. Here we will focus on one of the better characterized members of this class of compounds, benzo[*a*]pyrene B[*a*]P. B[*a*]P is produced along with other PAHs during the combustion of many organic substances including coal, cigarettes, and gasoline, and for this reason exposures to PAHs in the environment are relatively prevalent (*420*). The carcinogenic effects of PAHs in coal tar was first noticed in 1775 by Percival Pott, who observed a correlation between scrotal cancer and the occupation of chimney sweeping (*421*). B[*a*]P is a relatively unreactive 5-ring polycyclic planer hydrocarbon (Structure 1) (*422*):

Structure 1



However, B[*a*]P, like many other PAHs, is metabolized by components of the NADPH-dependent, cytochrome P450-containing monooxygenase microsomal enzymes through epoxidation to reactive electrophiles that can bind to such cellular nucleophiles as DNA, RNA, and proteins (*423,424*). The ultimate carcinogenic form is thought to be the 7β,8α-diol-9α,10α-epoxy-7,8,9,10-tetrahydrobenzo[*a*]pyrene (BPDE I) metabolite (*422,425–427*). BPDE I can covalently attach to DNA and form a variety of adducts, with the major adduct formed through linkage between the exocyclic 2-amino group of guanine and the C-10 position of BPDE I (*422,428*). It has also been reported that the process of metabolizing B[*a*]P to its reactive metabolites through the generation of radical cations results in the generation DNA adducts that undergo rapid depurination and contribute significantly to the carcinogenic properties of B[*a*]P (*429,430*). Exposure to B[*a*]P and other PAH carcinogens, which generate bulky DNA adducts and apurinic sites that can be further degraded to DNA strand breaks, has been shown to result in inhibition of DNA synthesis and induction of S phase cell cycle arrest (*431–437*). It is likely that the persistence of BPDE I–DNA adducts and other unrepaired lesions generated after exposure to B[*a*]P during the process of DNA replication can result in generation of base-substitution mutations and chromosomal aberrations (*332,437–441*).

It is important to note that there are many other classes of environmental agents known to modify DNA and to be potent carcinogens. Included among these agents are aflatoxin and the aromatic and heterocyclic amines. Aflatoxin is a potent hepatocarcinogen produced by fungal contamination of foods and readily forms DNA adducts (*442*). The heterocyclic and aromatic amines also readily form DNA adducts and have widespread industrial uses and occur in foodstuffs, cooked meat, and tobacco smoke (*443,444*). Although the effects of these and other important environmental mutagenic toxins upon cell cycle checkpoint function are as yet poorly understood, their ability to induce mutations in critical cell cycle regulatory genes, as has been demonstrated in the case of aflatoxin-induced mutations of p53 (*445*), could seriously compromise checkpoint function.

DNA Repair Ability and Cancer Risk

The importance of DNA repair in maintaining genomic integrity and protecting against development of cancers has been shown in studies involving cancer patients and cancer-prone individuals as well as in studies involving genetically altered mice that exhibit deficiencies in DNA repair. The connection between DNA repair defects and human cancer predisposition was first recognized by Cleaver (*344,345*) in studying cells from individuals with *Xeroderma pigmentosum*. These cells were defective in the nucleotide excision repair pathway required to remove UV-induced DNA lesions. Studies of phytohemagglutinin-stimulated blood lymphocyte cultures from individuals with breast cancer and from individuals from familial breast cancer families showed that these cells were deficient in their DNA repair capacity compared with lymphocytes from control individuals, as measured indirectly by quantifying the generation of chromatid abnormalities following DNA damage (*446,447*). The *BRCA1* and *BRCA2* gene products, which when mutated predispose individuals to development of breast cancer, have been reported to play a role of in DNA repair and cell cycle checkpoint function (*448–457*). Defects in DNA repair, specifically in mismatch repair pathways, are important in the development of a variety of human cancers including cervix–uterine cancer, lung cancer, head and neck cancers, colorectal cancer, and basal cell carcinoma (*458–473*). The postreplication DNA mismatch repair system recognizes and removes inappropriately paired nucleotides that may have been generated by DNA replication errors, errors generated in DNA recombination events, or base damage following exposures to genotoxic agents (*465,474,475*). Mutations in DNA mismatch repair pathways have been reported to affect cell cycle checkpoint function, with the best evidence to date demonstrating an important role of the *MLH1* gene product in a p53-independent G_2 checkpoint response to DNA damage generated by 6-thioguanine, MNNG, and IR exposures (*227,419,476,477*). Furthermore, mice deficient in DNA mismatch repair have increased susceptibility to development of neoplasia (*478–481*).

Summary

Neoplastic progression has been demonstrated to involve increasing genetic instability (*201,470,482–488*). The information gained from studies of the molecular mechanisms governing cell cycle control, DNA repair, and cell cycle checkpoint signaling in normal individuals and in individuals with heritable cancer syndromes, together with the effects of genotoxic substances on these biochemical pathways, demonstrates the importance of these molecular pathways in the maintenance of

genomic integrity. Loss of any aspect of these systems dramatically lessens DNA stability and cell viability and increases cancer susceptibility.

In particular, attenuation or ablation of cell cycle checkpoint signaling pathways results in a dramatic lessening of DNA stability in the face of genomic stress as well as lowered cellular viability and increased cancer susceptibility. These effects are particularly clear in studies involving caffeine-induced "checkpoint function over-ride" after DNA damage [for example (*244*)]. Similarly, the near-complete ablation of the G_1, S, and G_2 phase checkpoint functions in cells from individuals with AT and the loss of the G_1 checkpoint function in p53 mutant cells (accompanied by an attenuation of the G_2 checkpoint function and increased genomic instability) supports the view that cell cycle checkpoint responses function to allow the damaged cell time to repair damage, or alternatively to undergo apoptosis or enter into a permanent G_0-like state.

One important and interesting area for future study is the impact of nongenotoxic chemicals on cell cycle checkpoint function. A number of chemicals found in the environment, compounds such as benzene and 1,4-dioxane, fail to show mutagenic properties as measured in *Salmonella* mutagenesis assays, yet have the ability to induce tumors in rodents (*489*). The mechanism of induction of neoplasia by these environmental chemicals and their effects on cell cycle checkpoint function are not yet clearly understood. However, the study of these agents may give insight into both checkpoint signal transduction pathways and mechanisms of carcinogenesis. It is possible for example, that a nongenotoxic environmental carcinogen may function by ablating some aspects of cell cycle checkpoint function, perhaps leading to genetic instability or heritable alterations of the genome. Interestingly, caffeine, which has been found to have a significant impact on cell cycle checkpoint function (see above), is nonmutagenic in *Salmonella* mutagenesis assays (*490*).

The current model of the cell cycle checkpoint signaling in response to cellular damage and the generation of DNA strand breaks that result in both the G_1 and G_2 checkpoint delays involves activation of the ATM protein, which leads to both p53 and Chk1 activation. p53 initiates p21 transcription and the inhibition of cyclin/Cdk activity. Chk1 activation results presumably in altered CDC25 phosphatase localization, and hence lack of activation of cyclin/Cdk protein kinase complexes. Although less is known about the S phase checkpoint function, signaling through this pathway is known to be ATM-dependent and involves cyclin/Cdk inhibition and the suppression of DNA synthesis.

Together the above data indicate that cell cycle checkpoint responses *a*) are active signaling pathways dependent upon a number of different gene products, *b*) play a vital role in maintaining genomic stability, *c*) generate a transient delay in the progression through the cell cycle, *d*) may be either wholly or partially ablated by the loss/mutation of a single gene such as ATM or p53, and *e*) may be initiated by a wide variety of genotoxic agents that may exert very different effects on the cell. Our increasing understanding of cell cycle checkpoint signaling pathways may help in the design of more efficacious therapeutic strategies for treatment of cancers and other diseases that develop as a consequence of exposures to environmental genotoxins. Furthermore, understanding the role of cell cycle checkpoint responses to environmental exposures promises to aid in the development of more efficacious approaches to disease prevention. Such insight will provide us with a better understanding of the risks associated with exposures for the general population. Moreover, such data may allow more accurate assessment of risk for specific subpopulations of individuals predisposed to development of certain diseases because of genetic susceptibilities. Appropriate measures then can be designed to minimize those exposures associated with significant risks.

ACKNOWLEDGMENTS: The authors acknowledge the helpful comments and encouragement of K.R. Tindall, D.A. Alcorta, and R.W. Tennant.

REFERENCES AND NOTES

1. Magner LN. A History of Medicine. New York:Marcel Dekker, 1992.
2. Ford JB. The earliest views. Sci Am 278:50–53 (1998).
3. Baserga R. The Biology of Cell Reproduction. Cambridge, MA:Harvard University Press, 1985.
4. Howard A, Pelc SR. Synthesis of nucleoprotein in bean root cells. Nature 167:599–600 (1951).
5. Howard A, Pelc SR. Synthesis of deoxyribonucleic acid in normal and irradiated cells and its relation to chromosome breakage. Heredity 6:261–273 (1953).
6. Pardee AB, Dubrow R, Hamlin JL, Kletzien RF. Animal cell cycle. Annu Rev Biochem 47:715–750 (1978).
7. Baserga R. Growth in size and cell DNA replication. Exp Cell Res 151:1–5 (1984).
8. Murray A, Hunt T. The Cell Cycle: An Introduction. New York:W.H. Freeman and Co., 1993.
9. Nasmyth K. Viewpoint: Putting the cell cycle in order. Science 274:1643–1645 (1996).
10. Rao PN, Johnson RT. Mammalian cell fusion: studies on the regulation of DNA synthesis and mitosis. Nature 225:159–164 (1970).
11. Johnson RT, Rao PN. Mammalian cell fusion: induction of premature chromosome condensation in interphase nuclei. Nature 226:717–722 (1970).
12. Hartwell LH, Weinert TA. Checkpoints: controls that ensure the order of cell cycle events. Science 246:629–633 (1989).
13. Kastan MB, ed. Checkpoint Controls and Cancer. Plainview, NY:Cold Spring Harbor Laboratory Press, 1997.
14. Nigg EA. Cyclin-dependent protein kinases: key regulators of the eukaryotic cell cycle. Bioessays 17:471–480 (1995).
15. Morgan DO. Principles of CDK regulation. Nature 374:131–134 (1995).
16. Iliakis G. Cell cycle regulation in irradiated and nonirradiated cells. Semin Oncol 24:602–615 (1997).
17. Matsushime H, Roussel MF, Ashmun RA, Sherr CJ. Colony-stimulating factor 1 regulates novel cyclins during the G_1 phase of the cell cycle. Cell 65:701–713 (1991).
18. Pardee AB. G_1 events and regulation of cell proliferation. Science 246:603–608 (1989).
19. Hatakeyama M, Weinberg RA. The role of RB in cell cycle control. Prog Cell Cycle Res 1:9–19 (1995).
20. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 351:453–456 (1991).
21. Matsushime H, Quelle DE, Shurtleff SA, Shibuya M, Sherr CJ, Kato JY. D-Type cyclin-dependent kinase activity in mammalian cells. Mol Cell Biol 14:2066–2076 (1994).
22. Ajchenbaum F, Ando K, DeCaprio JA, Griffin JD. Independent regulation of human D-type cyclin gene expression during G_1 phase in primary human T lymphocytes. J Biol Chem 268: 4113–4119 (1993).
23. Won K-A, Xiong Y, Beach D, Gilman MZ. Growth-regulated expression of D-type cyclin genes in human diploid fibroblasts. Proc Natl Acad Sci USA 89:9910–9914 (1992).
24. Cocks BG, Vairo G, Bodrug SE, Hamilton JA. Suppression of growth factor-induced CYL1 cyclin gene expression by antiproliferative agents. J Biol Chem 267:12307–12310 (1992).
25. Matsushime H, Roussel MF, Sherr CJ. Novel mammalian cyclins (CYL genes) expressed during G_1 Cold Spring Harbor Symp Quant Biol 56:69–74 (1991).
26. Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G. Cyclin D1 is a nuclear protein required for cell cycle progression in G_1. Genes Dev 7:812–821 (1993).
27. Quelle DE, Ashmun RA, Shurtleff SA, Kato J-Y, Bar-Sagi D, Roussel MF, Sherr CJ. Overexpression of mouse D-type cyclins accelerates G_1 phase in rodent fibroblasts. Genes Dev 7:1559–1571 (1993).
28. Motokura T, Bloom T, Kim HG, Juppner H, Ruderman JV, Kronenberg HM, Arnold A. A novel cyclin encoded by a *bcl*1-linked candidate oncogene. Nature 350:512–515 (1991).
29. Seto M, Yamamoto K, Lida S, Akao Y, Utsumi KR, Kubonishi I, Miyoshi I, Ohtsuki T, Yawata Y, Namba M, et al. Gene rearrangement and

over-expression of PRAD1 in lymphoid malignancy with t(11;14)-(q13;q32) translocation. Oncogene 7:1401–1406 (1992).
30. Lammie GA, Fantl V, Smith R, Schuuring E, Brookes S, Michalides R, Dickson C, Arnold A, Peters G. D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene 6:439–444 (1991).
31. Resnitzky D, Gossen M, Bujard H, Reed SI. Acceleration of the G_1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol Cell Biol 14:1669–1679 (1994).
32. Sherr CJ. G_1 phase progression: cycling on cue. Cell 79:551–555 (1994).
33. Kiyokawa H, Busquets X, Powell CT, Ngo L, Rifkind RA, Marks PA. Cloning of a D-type cyclin from murine erythroleukemia cells. Proc Natl Acad Sci USA 89:2444–2447 (1992).
34. Motokura T, Keyomarsi K, Kronenberg HM, Arnold A. Cloning and characterization of human cyclin D3, a cDNA closely related in sequence to the PRAD1/cyclin D1 proto-oncogene. J Biol Chem 267:20412–20415 (1992).
35. Fantl V, Stamp G, Andrews A, Rosewell I, Dickson C. Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev 9:2364–2372 (1995).
36. Sicinski P, Donaher JL, Geng Y, Parker SB, Gardner H, Park MY, Robker RL, Richards JS, McGinnis LK, Biggers JD, .et al. Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. Nature 384:470–474 (1996).
37. Peters G. The D-type cyclins and their role in tumorigenesis. J Cell Sci:89–96 (1994).
38. Meyerson M, Harlow E. Identification of G_1 kinase activity for cdk6, a novel cyclin D partner. Mol Cell Biol 14:2077–2086 (1994).
39. Matsushime H, Ewen ME, Strom DK, Kato JY, Hanks SK, Roussel MF, Sherr CJ. Identification and properties of an atypical catalytic subunit ($p34^{PSK-J3}$/cdk4) for mammalian D-type G_1 cyclins. Cell 71:323–334 (1992).
40. Xiong Y, Zhang H, Beach D. D-type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell 71: 505–514 (1992).
41. Tam SW, Theodoras AM, Shay JW, Draetta GF, Pagano M. Differential expression and regulation of cyclin D1 protein in normal and tumor human cells: association with Cdk4 is required for cyclin D1 function in G_1 progression. Oncogene 9:2663–2674 (1994).
42. Hunter T, Pines J. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell 79:573–582 (1994).
43. Khatib ZA, Matsushime H, Valentine M, Shapiro DN, Sherr CJ, Look AT. Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res 53:5535–5541 (1993).
44. Schmidt EE, Ichimura K, Reifenberger G, Collins VP. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 54:6321–6324 (1994).
45. Lukas J, Bartkova J, Muller H, Spitkovsky D, Kjerulff AA, Jansendurr P, Strauss M, Bartek J. DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cells requirement for cyclin D1 function in G_1. J Cell Biol 125:625–638 (1994).
46. Herwig S, Strauss M. The retinoblastoma protein: a master regulator of cell cycle, differentiation and apoptosis. Eur J Biochem 246:581–601 (1997).
47. Nevins JR. E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science 258:424–429 (1992).
48. Dou QP, Fridovich Keil JL, Pardee AB. Inducible proteins binding to the murine thymidine kinase promoter in late G_1/S phase. Proc Natl Acad Sci USA 88:1157–1161 (1991).
49. Pearson BE, Nasheuer HP, Wang TS. Human DNA polymerase α gene: sequences controlling expression in cycling and serum-stimulated cells. Mol Cell Biol 11:2081–2095 (1991).
50. Dou QP, Zhao SC, Levin AH, Wang J, Helin K, Pardee AB. G_1/S-regulated E2F-containing protein complexes bind to the mouse thymidine kinase gene promoter. J Biol Chem 269:1306–1313 (1994).
51. Furukawa Y, Terui Y, Sakoe K, Ohta M, Saito M. The role of cellular transcription factor E2F in the regulation of cdc2 mRNA expression and cell cycle control of human hematopoietic cells. J Biol Chem 269:26249–26258 (1994).
52. Johnson DG, Ohtani K, Nevins JR. Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression. Genes Dev 8:1514–1525 (1994).
53. Lee HH, Chiang WH, Chiang SH, Liu YC, Hwang J, Ng SY. Regulation of cyclin D1, DNA topoisomerase I, and proliferating cell nuclear antigen promoters during the cell cycle. Gene Expr 4:95–109 (1995).
54. Ohtani K, DeGregori J, Nevins JR. Regulation of the cyclin E gene by transcription factor E2F1. Proc Natl Acad Sci USA 92:12146–12150 (1995).
55. Schulze A, Zerfass K, Spitkovsky D, Middendorp S, Berges J, Helin K, Jansen-Durr P, Henglein B. Cell cycle regulation of the cyclin A gene promoter is mediated by a variant E2F site. Proc Natl Acad Sci USA 92:11264–11268 (1995).
56. Tommasi S, Pfeifer GP. *In vivo* structure of the human cdc2 promoter: release of a p130-E2F-4 complex from sequences immediately upstream of the transcription initiation site coincides with induction of cdc2 expression. Mol Cell Biol 15:6901–6913 (1995).
57. Botz J, Zerfass-Thome K, Spitkovsky D, Delius H, Vogt B, Eilers M, Hatzigeorgiou A, Jansen-Durr P. Cell cycle regulation of the murine cyclin E gene depends on an E2F binding site in the promoter. Mol Cell Biol 16:3401–3409 (1996).
58. Geng Y, Eaton EN, Picon M, Roberts JM, Lundberg AS, Gifford A, Sardet C, Weinberg RA. Regulation of cyclin E transcription by E2Fs and retinoblastoma protein. Oncogene 12:1173–1180 (1996).
59. Oswald F, Dobner T, Lipp M. The E2F transcription factor activates a replication-dependent human H2A gene in early S phase of the cell cycle. Mol Cell Biol 16:1889–1895 (1996).
60. Slansky JE, Farnham PJ. Transcriptional regulation of the dihydrofolate reductase gene. Bioessays 18:55–62 (1996).
61. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev 12:2245–2262 (1998).
62. Koff A, Cross F, Fisher A, Schumacher J, Leguellec K, Philippe M, Roberts JM. Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family. Cell 66:1217–1228 (1991).
63. Koff A, Giordano A, Desai D, Yamashita K, Harper JW, Elledge S, Nishimoto T, Morgan DO, Franza BR, Roberts JM. Formation and activation of a cyclin E-cdk2 complex during the G_1 phase of the human cell cycle. Science 257:1689–1694 (1992).
64. Lew DJ, Dulic V, Reed SI. Isolation of three novel human cyclins by rescue of G_1 cyclin (Cln) function in yeast. Cell 66:1197–1206 (1991).
65. Dulic V, Lees E, Reed S. Association of human cyclin E with a periodic G_1-S phase protein kinase. Science 257:1958–1961 (1992).
66. Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM, Pagano M. Human cyclin E, a nuclear protein essential for the G_1-to-S phase transition. Mol Cell Biol 15:2612–2624 (1995).
67. Pagano M, Pepperkok R, Lukas J, Baldin V, Ansorge W, Bartek J, Draetta G. Regulation of the cell cycle by the cdk2 protein kinase in cultured human fibroblasts. J Cell Biol 121:101–111 (1993).
68. Tsai LH, Lees E, Faha B, Harlow E, Riabowol K. The cdk2 kinase is required for the G_1-to-S transition in mammalian cells. Oncogene 8:1593–1602 (1993).
69. Keyomarsi K, Herliczek TW. The role of cyclin E in cell proliferation, development and cancer. Prog Cell Cycle Res 3:171–191 (1997).
70. Lundberg AS, Weinberg RA. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol 18:753–761 (1998).
71. Resnitzky D, Hengst L, Reed SI. Cyclin A-associated kinase activity is rate limiting for entrance into S phase and is negatively regulated in G_1 by $p27^{Kip1}$. Mol Cell Biol 15:4347–4352 (1995).
72. Minshull J, Golsteyn R, Hill CS, Hunt T. The A- and B-type cyclin associated cdc2 kinases in *Xenopus* turn on and off at different times in the cell cycle. EMBO J 9:2865–2875 (1990).
73. Pines J, Hunter T. Human cyclin A is adenovirus E1A-associated protein p60 and behaves differently from cyclin B. Nature (Lond) 346:760–763 (1990).
74. Girard F, Strausfeld U, Fernandez A, Lamb NJ. Cyclin A is required for the onset of DNA replication in mammalian fibroblasts. Cell 67:1169–1179 (1991).
75. Lehner CF, O'Farrell PH. The roles of Drosophila cyclins A and B in mitotic control. Cell 61:535–547 (1990).
76. Walker DH, Maller JL. Role for cyclin A in the dependence of mitosis on completion of DNA replication. Nature 354:314–317 (1991).
77. Rosenblatt J, Gu Y, Morgan DO. Human cyclin-dependent kinase 2 is activated during the S and G_2 phases of the cell cycle and associates with cyclin A. Proc Natl Acad Sci USA 89:2824–2828 (1992).
78. Fang F, Newport JW. Evidence that the G_1-S and G_2-M transitions are controlled by different cdc2 proteins in higher eukaryotes. Cell 66:731–742 (1991).
79. Th'ng JP, Wright PS, Hamaguchi J, Lee MG, Norbury CJ, Nurse P, Bradbury EM. The FT210 cell line is a mouse G2 phase mutant with a temperature-sensitive CDC2 gene product. Cell 63:313–324 (1990).
80. Pagano M, Pepperkok R, Verde F, Ansorge W, Draetta G. Cyclin A is required at two points in the human cell cycle. EMBO J 11:961–971 (1992).

81. Peeper DS, Parker LL, Ewen ME, Toebes M, Hall FL, Xu M, Zantema A, Van der Eb AJ, Piwnica-Worms H. A-Type and B-type cyclins differentially modulate substrate specificity of cyclin-Cdk complexes. EMBO J 12:1947–1954 (1993).
82. Knudsen ES, Buckmaster C, Chen TT, Feramisco JR, Wang JYJ. Inhibition of DNA synthesis by RB: effects on G_1/S transition and S-phase progression. Genes Dev 12:2278–2292 (1998).
83. Philips A, Huet X, Plet A, Le Cam L, Vie A, Blanchard JM. The retinoblastoma protein is essential for cyclin A repression in quiescent cells. Oncogene 16:1373–1381 (1998).
84. Dalton S. Cell cycle regulation of the human cdc2 gene. EMBO J 11:1797–1804 (1992).
85. Chao Y, Shih YL, Chiu JH, Chau GY, Lui WY, Yang WK, Lee SD, Huang TS. Overexpression of cyclin A but not Skp 2 correlates with the tumor relapse of human hepatocellular carcinoma. Cancer Res 58:985–990 (1998).
86. Lee M, Nurse P. Cell cycle control genes in fission yeast and mammalian cells. Trends Genet 4:287–290 (1988).
87. Lohka MJ, Hayes MK, Maller JL. Purification of maturation-promoting factor, an intracellular regulator of early mitotic events. Proc Natl Acad Sci USA 85:3009–3013 (1988).
88. Gautier J, Norbury C, Lohka M, Nurse P, Maller J. Purified maturation-promoting factor contains the product of a *Xenopus* homolog of the fission yeast cell cycle control gene $cdc2^+$. Cell 54:433–439 (1988).
89. Arion D, Meijer L, Brizuela L, Beach D. cdc2 is a component of the M phase-specific histone H1 kinase: evidence for identity with MPF. Cell 55:371–378 (1988).
90. Dunphy WG, Brizuela L, Beach D, Newport J. The Xenopus cdc2 protein is a component of MPF, a cytoplasmic regulator of mitosis. Cell 54:423–431 (1988).
91. Labbe JC, Capony JP, Caput D, Cavadore JC, Derancourt J, Kaghad M, Lelias JM, Picard A, Doree M. MPF from starfish oocytes at first meiotic metaphase is a heterodimer containing one molecule of cdc2 and one molecule of cyclin B EMBO J 8:3053–3058 (1989).
92. Gautier J, Minshull J, Lohka M, Glotzer M, Hunt T, Maller JL. Cyclin is a component of maturation-promoting factor from *Xenopus*. Cell 60:487–494 (1990).
93. Pines J, Hunter T. Isolation of a human cyclin cDNA: evidence for cyclin mRNA and protein regulation in the cell cycle and for interaction with $p34^{cdc2}$. Cell 58:833–846 (1989).
94. Pines J, Hunter T. Human cyclins A and B1 are differentially located in the cell and undergo cell cycle-dependent nuclear transport. J Cell Biol 115:1–17 (1991).
95. Gallant P, Nigg EA. Cyclin B2 undergoes cell cycle-dependent nuclear translocation and, when expressed as a non-destructible mutant, causes mitotic arrest in HeLa cells. J Cell Biol 117:213–224 (1992).
96. Gallant P, Nigg EA. Identification of a novel vertebrate cyclin: cyclin-B3 shares properties with both A- and B-type cyclins. EMBO J 13:595–605 (1994).
97. Jackman M, Firth M, Pines J. Human cyclins B1 and B2 are localized to strikingly different structures: B1 to microtubules, B2 primarily to the Golgi apparatus. EMBO J 14:1646–1654 (1995).
98. Ookata K, Hisanaga S, Okano T, Tachibana K, Kishimoto T. Relocation and distinct subcellular localization of $p34^{cdc2}$-cyclin B complex at meiosis reinitiation in starfish oocytes. EMBO J 11:1763–1772 (1992).
99. Pines J, Hunter T. The differential localization of human cyclins A and B is due to a cytoplasmic retention signal in cyclin B. EMBO J 13:3772–3781 (1994).
100. Li J, Meyer AN, Donoghue DJ. Nuclear localization of cyclin B1 mediates its biological activity and is regulated by phosphorylation. Proc Natl Acad Sci USA 94:502–507 (1997).
101. Erikson E, Maller JL. Biochemical characterization of the p34cdc2 protein kinase component of purified maturation-promoting factor from Xenopus eggs. J Biol Chem 264:19577–19582 (1989).
102. Brandeis M, Rosewell I, Carrington M, Crompton T, Jacobs MA, Kirk J, Gannon J, Hunt T. Cyclin B2-null mice develop normally and are fertile whereas cyclin B1-null mice die *in utero*. Proc Natl Acad Sci USA 95:4344–4349 (1998).
103. Sherr CJ, Roberts JM. Inhibitors of mammalian G_1 cyclin-dependent kinases. Genes Dev 9:1149–1163 (1995).
104. Draetta G. Cell cycle control in eukaryotes: molecular mechanisms of cdc2 activation. Trends Biochem Sci 15:378–383 (1990).
105. Norbury C, Nurse P. Animal cell cycles and their control. Annu Rev Biochem 61:441–470 (1993).
106. Morgan DO. Cyclin-dependent kinases: Engines, clocks, and microprocessors. Annu Rev Cell Dev Biol 13:261–291 (1997).
107. Nigg EA. Cyclin-dependent kinase 7: at the crossroads of transcription, DNA repair and cell cycle control? Curr Opin Cell Biol 8:312–317 (1996).
108. Draetta GF. Cell cycle: Will the real Cdk-activating kinase please stand up? Curr Biol 7:50–52 (1997).
109. Gould KL, Nurse P. Tyrosine phosphorylation of the fission yeast cdc^{2+} protein kinase regulates entry into mitosis. Nature 342:39–45 (1989).
110. Norbury C, Blow J, Nurse P. Regulatory phosphorylation of the $p34^{cdc2}$ protein kinase in vertebrates. EMBO J 10:3321–3329 (1991).
111. McGowan CH, Russell P. Human Wee1 kinase inhibits cell division by phosphorylating $p34^{cdc2}$ exclusively on Tyr15. EMBO J 12:75–85 (1993).
112. Booher RN, Holman PS, Fattaey A. Human Myt1 is a cell cycle-regulated kinase that inhibits Cdc2 but not Cdk2 activity. J Biol Chem 272: 22300–22306 (1997).
113. Parker LL, Atherton-Fessler S, Lee MS, Ogg S, Falk JL, Swenson KI, Piwnica-Worms H. Cyclin promotes the tyrosine phosphorylation of $p34^{cdc2}$ in a wee1+ dependent manner. EMBO J 10:1255–1263 (1991).
114. Lundgren K, Walworth N, Booher R, Dembski M, Kirschner M, Beach D. mik1 and wee1 cooperate in the inhibitory tyrosine phosphorylation of cdc2. Cell 64:1111–1122 (1991).
115. Atherton-Fessler S, Parker LL, Geahlen RL, Piwnica-Worms H. Mechanisms of $p34^{cdc2}$ regulation. Mol Cell Biol 13:1675–1685 (1993).
116. Strausfeld U, Labbe JC, Fesquet D, Cavadore JC, Picard A, Sadhu K, Russell P, Doree M. Dephosphorylation and activation of a $p34^{cdc2}$/cyclin B complex *in vitro* by human CDC25 protein. Nature 351:242–245 (1991).
117. Gautier J, Solomon MJ, Booher RN, Bazan JF, Kirschner MW. cdc25 is a specific tyrosine phosphatase that directly activates $p34^{cdc2}$. Cell 67:197–211 (1991).
118. Kumagai A, Dunphy WG. The cdc25 protein controls tyrosine dephosphorylation of the cdc2 protein in a cell-free system. Cell 64:903–914 (1991).
119. Hoffmann I, Clarke PR, Marcote MJ, Karsenti E, Draetta G. Phosphorylation and activation of human cdc25-C by cdc2/cyclin-B and its involvement in the self-amplification of MPF at mitosis. EMBO J 12:53–63 (1993).
120. Kumagai A, Dunphy WG. Regulation of the cdc25 protein during the cell cycle in Xenopus extracts. Cell 70:139–151 (1992).
121. Huang LC, Clarkin KC, Wahl GM. Sensitivity and selectivity of the DNA damage sensor responsible for activating p53-dependent G_1 arrest. Proc Natl Acad Sci USA 93:4827–4832 (1996).
122. Elledge SJ. Cell cycle checkpoints: preventing an identity crisis. Science 274:1664–1672 (1996).
123. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 266:1821–1828 (1994).
124. Little JB. Delayed initiation of DNA synthesis in irradiated human diploid cells. Nature 218:1064–1065 (1968).
125. Kastan MB, Onyekere O, Sidransky D, Volgelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304–6311 (1991).
126. Maltzman W, Czyzyk L. UV irradiation stimulates levels of p53 cellular tumour antigen in nontransformed mouse cells. Mol Cell Biol 4:1689–1694 (1984).
127. Campbell C, Quinn AG, Angus B, Farr PM, Rees JL. Wavelength specific patterns of p53 induction in human skin following exposure to UV radiation. Cancer Res 53:2697–2699 (1993).
128. Nelson WG, Kastan MB. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 14:1815–1823 (1994).
129. Di Leonardo A, Linke SP, Clarkin K, Wahl GM. DNA damage triggers a prolonged p53-dependent G_1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev 8:2540–2551 (1994).
130. Khanna KK, Beamish H, Yan J, Hobson K, Williams R, Dunn I, Lavin MF. Nature of G_1/S cell cycle checkpoint defect in *Ataxia-telangiectasia*. Oncogene 11:609–618 (1995).
131. Kern SE, Kinzler KW, Bruskin A, Jarosz D, Friedman P, Prives C, Vogelstein B. Identification of p53 as a sequence-specific DNA-binding protein. Science 252:1708–1711 (1991).
132. Funk WD, Pak DT, Karas RH, Wright WE, Shay JW. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol 12:2866–2871 (1992).
133. Kastan MB, Zhan Q, el DW, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Fornace AJJ. A mammalian cell cycle checkpoint pathway utilizing p53 and *GADD45* is defective in *Ataxia-telangiectasia*. Cell 71:587–597 (1992).
134. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y, et al. WAF1/CIP1 is induced in *p53*-mediated G_1 arrest and apoptosis. Cancer Res 54:1169–1174 (1994).
135. Ragimov N, Krauskopf A, Navot N, Rotter V, Oren M, Aloni Y. Wild-type but not mutant p53 can repress transcription initiation *in vitro* by interfering with the binding of basal transcription factors

to the TATA motif. Oncogene 8:1183–1193 (1993).
136. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 366:701–704 (1993).
137. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G_1 cyclin-dependent kinases. Cell 75:805–816 (1993).
138. Dulic V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper JW, Elledge SJ, Reed SI. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G_1 arrest. Cell 76:1013–1023 (1994).
139. Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai LH, Zhang PM, Dobrowolski S, Bai C, Connellcrowley L, Swindell E, Fox MP, Wei N. Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 6:387–400 (1995).
140. Dulic V, Stein GH, Far DF, Reed SI. Nuclear accumulation of $p21^{Cip1}$ at the onset of mitosis: a role at the G_2/M-phase transition. Mol Cell Biol 18:546–557 (1998).
141. Deng CX, Zhang PM, Harper JW, Elledge SJ, Leder P. Mice lacking $p21^{CIP1/WAF1}$ undergo normal development, but are defective in G_1 checkpoint control. Cell 82:675–684 (1995).
142. Jiang H, Lin J, Su ZZ, Collart FR, Huberman E, Fisher PB. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene 9:3397–3406 (1994).
143. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 54:3391–3395 (1994).
144. Macleod KF, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K, Vogelstein B, Jacks T. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 9:935–944 (1995).
145. Serfas MS, Goufman E, Feuerman MH, Gartel AL, Tyner AL. p53-independent induction of $p21^{WAF1/CIP1}$ expression in pericentral hepatocytes following carbon tetrachloride intoxication. Cell Growth Differ 8:951–961 (1997).
146. Parker SB, Eichele G, Zhang P, Rawls A, Sands AT, Bradley A, Olson EN, Harper JW, Elledge SJ. p53-independent expression of $p21^{Cip1}$ in muscle and other terminally differentiating cells. Science 267:1024–1027 (1995).
147. Zhang H, Hannon GJ, Beach D. p21-containing cyclin kinases exist in both active and inactive states. Genes Dev 8:1750–1758 (1994).
148. Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369:574–578 (1994).
149. Cistulli CA, Kaufmann WK. p53-dependent signaling sustains DNA replication and enhances clonogenic survival in 254 nm ultraviolet-irradiated human fibroblasts. Cancer Res 58:1993–2002 (1998).
150. Toyoshima H, Hunter T. p27, a novel inhibitor of G_1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78:67–74 (1994).
151. Matsuoka S, Edwards MC, Bai C, Parker S, Zhang PM, Baldini A, Harper JW, Elledge SJ. $p57^{KIP2}$, a structurally distinct member of the $p21^{CIP1}$ Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 9:650–662 (1995).
152. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin-D/CDK4. Nature 366:704–707 (1993).
153. Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, Peters G, Bartek J. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 375:503–506 (1995).
154. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA. Role of the INK4a locus in tumor suppression and cell mortality. Cell 85:27–37 (1996).
155. Otterson GA, Khleif SN, Chen W, Coxon AB, Kaye FJ. CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2'deoxycytidine. Oncogene 11:1211–1216 (1995).
156. Ichikawa Y, Yoshida S, Koyama Y, Hirai M, Ishikawa T, Nishida M, Tsunoda H, Kubo T, Miwa M, Uchida K. Inactivation of p16/CDKN2 and p15/MTS2 genes in different histological types and clinical stages of primary ovarian tumors. Int J Cancer 69:466–470 (1996).
157. Lo KW, Cheung ST, Leung SF, van-Hasselt A, Tsang YS, Mak KF, Chung YF, Woo JK, Lee JC, Huang DP. Hypermethylation of the p16 gene in nasopharyngeal carcinoma. Cancer Res 56: 2721–2725 (1996).
158. Foulkes WD, Flanders TY, Pollock PM, Hayward NK. The CDKN2A (p16) gene and human cancer. Mol Med 3:5–20 (1997).
159. Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, Grosveld G, Sherr CJ. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product $p19^{ARF}$. Cell 91:649–659 (1997).
160. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83: 993–1000 (1995).
161. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, et al. The Ink4a tumor suppressor gene product, $p19^{Arf}$, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92:713–723 (1998).
162. Gu Y, Rosenblatt J, Morgan DO. Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. EMBO J 11:3995–4005 (1992).
163. Sebastian B, Kakizuka A, Hunter T. Cdc25M2 activation of cyclin-dependent kinases by dephosphorylation of threonine-14 and tyrosine-15. Proc Natl Acad Sci USA 90:3521–3524 (1993).
164. Terada Y, Tatsuka M, Jinno S, Okayama H. Requirement for tyrosine phosphorylation of Cdk4 in G_1 arrest induced by ultraviolet irradiation. Nature 376:358–362 (1995).
165. Tiefenbrun N, Melamed D, Levy N, Resnitzky D, Hoffman I, Reed SI, Kimchi A. Alpha interferon suppresses the cyclin D3 and cdc25A genes, leading to a reversible G_0-like arrest. Mol Cell Biol 16:3934–3944 (1996).
166. Jinno S, Suto K, Nagata A, Igarashi M, Kanaoka Y, Nojima H, Okayama H. Cdc25A is a novel phosphatase functioning early in the cell cycle. EMBO J 13:1549–1556 (1994).
167. Makino F, Okada S. Effects of ionizing radiation on DNA replication in cultured mammalian cells. Radiat Res 62:37–51 (1975).
168. Painter RB, Young BR. X-ray-induced inhibition of DNA synthesis in Chinese hamster ovary, human HeLa, and mouse L cells. Radiat Res 64:648–656 (1975).
169. Painter RB, Young BR. Formation of nascent DNA molecules during inhibition of replicon initiation in mammalian cells. Biochim Biophys Acta 418:146–153 (1976).
170. Painter RB, Young BR. Radiosensitivity in *Ataxia-telangiectasia*: a new explanation. Proc Natl Acad Sci USA 77:7315–7317 (1980).
171. Larner JM, Lee H, Hamlin JL. Radiation effects on DNA synthesis in a defined chromosomal replicon. Mol Cell Biol 14:1901–1908 (1994).
172. Cleaver JE, Rose R, Mitchell DL. Replication of chromosomal and episomal DNA in X-ray-damaged human cells: a *cis*- or *trans*-acting mechanism? Radiat Res 124:294–299 (1990).
173. Beamish H, Williams R, Chen P, Lavin MF. Defect in multiple cell cycle checkpoints in *Ataxia-telangiectasia* postirradiation. J Biol Chem 271:20486–20493 (1996).
174. Lock RB, Ross WE. Inhibition of $p34^{cdc2}$ kinase activity by etoposide or irradiation as a mechanism of G_2 arrest in Chinese hamster ovary cells. Cancer Res 50:3761-3766 (1990).
175. Lock RB, Ross WE. Possible role for $p34^{cdc2}$ kinase in etoposide-induced cell death of Chinese hamster ovary cells. Cancer Res 50:3767–3771 (1990).
176. Paules RS, Levedakou EN, Wilson SJ, Innes CL, Rhodes N, Tlsty TD, Galloway DA, Donehower LA, Tainsky MA, Kaufmann WK. Defective G_2 checkpoint function in cells from individuals with familial cancer syndromes. Cancer Res 55:1763–1773 (1995).
177. Herzinger T, Funk JO, Hillmer K, Eick D, Wolf DA, Kind P. Ultraviolet B irradiation-induced G_2 cell cycle arrest in human keratinocytes by inhibitory phosphorylation of the cdc2 cell cycle kinase. Oncogene 11:2151–2156 (1995).
178. Jin P, Gu Y, Morgan DO. Role of inhibitory CDC2 phosphorylation in radiation-induced G2 arrest in human cells. J Cell Biol 134:963–970 (1996).
179. O'Connor PM, Ferris DK, Hoffmann I, Jackman J, Draetta G, Kohn KW. Role of the cdc25C phosphatase in G_2 arrest induced by nitrogen mustard. Proc Natl Acad Sci USA 91:9480–9484 (1994).
180. Sanchez Y, Wong C, Thoma RS, Richman R, Wu RQ, Piwnica-Worms H, Elledge SJ. Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science 277:1497–1501 (1997).
181. Peng CY, Graves PR, Thoma RS, Wu ZQ, Shaw AS, Piwnica-Worms H. Mitotic and G_2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 277:1501–1505 (1997).
182. Weinert T. Cell cycle—a DNA damage checkpoint meets the cell cycle engine. Science 277: 1450–1451 (1997).
183. Zampetti-Bosseler F, Scott D. Cell death, chromosome damage and mitotic delay in normal human, *Ataxia telangiectasia* and retinoblastoma fibroblasts after X-irradiation. Int J Radiat Biol 39:547–558. (1981).
184. Scott D, Zampetti-Bosseler F. Cell cycle dependence of mitotic delay in X-irradiated normal and *Ataxia telangiectasia* fibroblasts. Int J Radiat Biol 42:679–683 (1982).

185. Nagasawa H, Latt SA, Lalande ME, Little JB. Effects of X-irradiation on cell cycle progression, induction of chromosomal aberrations and cell killing in *Ataxia telangiectasia* (AT) fibroblasts. Mutat Res 148:71–82 (1985).
186. Beamish H, Lavin MF. Radiosensitivity in *Ataxia-telangiectasia*: anomalies in radiation-induced cell cycle delay. Int J Radiat Biol 65:175–184 (1994).
187. Smeets MF, Mooren EH, Begg AC. The effect of radiation on G_2 blocks, cyclin B expression and cdc2 expression in human squamous carcinoma cell lines with different radiosensitivities. Radiother Oncol 33:217–227 (1994).
188. Toyoshima F, Moriguchi T, Wada A, Fukuda M, Nishida E. Nuclear export of cyclin B1 and its possible role in the DNA damage-induced G_2 checkpoint. EMBO J 17:2728–2735 (1998).
189. Jin P, Hardy S, Morgan DO. Nuclear localization of cyclin B1 controls mitotic entry after DNA damage. J Cell Biol 141:875–885 (1998).
190. Muschel RJ, Zhang HB, Iliakis G, McKenna WG. Cyclin B expression in HeLa cells during the G_2 block induced by ionizing radiation. Cancer Res 51:5113–5117 (1991).
191. Muschel RJ, Zhang HB, McKenna WG. Differential effect of ionizing radiation on the expression of cyclin A and cyclin B in HeLa cells. Cancer Res 53:1128–1135 (1993).
192. Maity A, Mckenna WG, Muschel RJ. Evidence for post-transcriptional regulation of cyclin B1 mRNA in the cell cycle and following irradiation in HeLa cells. EMBO J 14:603–609 (1995).
193. Lock RB. Inhibition of $p34^{cdc2}$ kinase activation, $p34^{cdc2}$ tyrosine dephosphorylation, and mitotic progression in Chinese hamster ovary cells exposed to etoposide. Cancer Res 52:1817–1822 (1992).
194. O'Connor PM, Ferris DK, Pagano M, Draetta G, Pines J, Hunter T, Longo DL, Kohn KW. G_2 delay induced by nitrogen mustard in human cells affects cyclin A/cdk2 and cyclin B1/cdc2-kinase complexes differently. J Biol Chem 268:8298–8308 (1993).
195. Barth H, Hoffmann I, Kinzel V. Radiation with 1 Gy prevents the activation of the mitotic inducers mitosis-promoting factor (MPF) and cdc25-C in HeLa cells. Cancer Res 56:2268–2272 (1996).
196. Poon RYC, Jiang W, Toyoshima H, Hunter T. Cyclin-dependent kinases are inactivated by a combination of p21 and Thr-14/Tyr-15 phosphorylation after UV-induced DNA damage. J Biol Chem 271:13283–13291 (1996).
197. Poon RYC, Chau MS, Yamashita K, Hunter T. The role of Cdc2 feedback loop control in the DNA damage checkpoint in mammalian cells. Cancer Res 57:5168–5178 (1997).
198. Rice RH, Steinmann KE, deGraffenried LA, Qin Q, Taylor N, Schlegel R. Elevation of cell cycle control proteins during spontaneous immortalization of human keratinocytes. Mol Biol Cell 4:185–194 (1993).
199. Steinmann KE, Pei XF, Stoppler H, Schlegel R, Schlegel R. Elevated expression and activity of mitotic regulatory proteins in human papillomavirus immortalized keratinocytes. Oncogene 9:387–394 (1994).
200. Kaufmann WK, Levedakou EN, Grady HL, Paules RS, Stein GH. Attenuation of G_2 checkpoint function precedes human cell immortalization. Cancer Res 55:7–11 (1995).
201. Kaufmann WK, Schwartz JL, Hurt JC, Byrd LL, Galloway DA, Levedakou E, Paules RS. Inactivation of G_2 checkpoint function and chromosomal destabilization are linked in human fibroblasts expressing human papillomavirus type 16 E6. Cell Growth Differ 8:1105–1114 (1997).
202. Chang THT, Ray FA, Thompson DA, Schlegel R. Disregulation of mitotic checkpoints and regulatory proteins following acute expression of SV40 large T antigen in diploid human cells. Oncogene 14:2383–2393 (1997).
203. Levedakou EN, Kaufmann WK, Alcorta DA, Galloway DA, Paules RS. p21ClP1 is not required for the early G_2 checkpoint response to ionizing radiation. Cancer Res 55:2500–2502 (1995).
204. Murray AW. The genetics of cell cycle checkpoints. Curr Opin Genet Dev 5:5–11 (1995).
205. Rudner AD, Murray AW. The spindle assembly checkpoint. Curr Opin Cell Biol 8:773–780 (1996).
206. Hardwick KG. The spindle checkpoint. Trends Genet 14:1–4 (1998).
207. King RW, Peters JM, Tugendreich S, Rolfe M, Hieter P, Kirschner MW. A 20S complex containing CDC27 and CDC16 catalyzes the mitosis-specific conjugation of ubiquitin to cyclin B. Cell 81:279–288 (1995).
208. King RW, Deshaies RJ, Peters JM, Kirschner MW. How proteolysis drives the cell cycle. Science 274:1652–1659 (1996).
209. Cohen-Fix O, Koshland D. The metaphase-to-anaphase transition: avoiding a mid-life crisis. Curr Opin Cell Biol 9:800–806 (1997).
210. Amon A, Irniger S, Nasmyth K. Closing the cell cycle circle in yeast: G_2 cyclin proteolysis initiated at mitosis persists until the activation of G_1 cyclins in the next cycle. Cell 77:1037–1050 (1994).
211. Sudakin V, Ganoth D, Dahan A, Heller H, Hershko J, Luca FC, Ruderman JV, Hershko A. The cyclosome, a large complex containing cyclin-selective ubiquitin ligase activity, targets cyclins for destruction at the end of mitosis. Mol Biol Cell 6:185–197 (1995).
212. Cohen-Fix O, Peters JM, Kirschner MW, Koshland D. Anaphase initiation in *Saccharomyces cerevisiae* is controlled by the APC-dependent degradation of the anaphase inhibitor Pds1p. Genes Dev 10:3081–3093 (1996).
213. Cohen-Fix O, Koshland D. The anaphase inhibitor of *Saccharomyces cerevisiae* Pds1p is a target of the DNA damage checkpoint pathway. Proc Natl Acad Sci USA 94:14361–14366 (1997).
214. Juang YL, Huang J, Peters JM, McLaughlin ME, Tai CY, Pellman D. APC-mediated proteolysis of Ase 1 and the morphogenesis of the mitotic spindle. Science 275:1311–1314 (1997).
215. Zieve GW, Turnbull D, Mullins JM, McIntosh JR. Production of large numbers of mitotic mammalian cells by use of the reversible microtubule inhibitor nocodazole. Nocodazole accumulated mitotic cells. Exp Cell Res 126:397–405 (1980).
216. Kung AL, Sherwood SW, Schimke RT. Cell line-specific differences in the control of cell cycle progression in the absence of mitosis. Proc Natl Acad Sci USA 87:9553–9557 (1990).
217. Rieder CL, Schultz A, Cole R, Sluder G. Anaphase onset in vertebrate somatic cells is controlled by a checkpoint that monitors sister kinetochore attachment to the spindle. J Cell Biol 127:1301–10 (1994).
218. Li XT, Nicklas RB. Mitotic forces control a cell-cycle checkpoint. Nature 373:630–632 (1995).
219. Fang GW, Yu HT, Kirschner MW. The checkpoint protein MAD2 and the mitotic regulator CDC20 form a ternary complex with the anaphase-promoting complex to control anaphase initiation. Genes Dev 12:1871–1883 (1998).
220. Hwang LH, Lau LF, Smith DL, Mistrot CA, Hardwick KG, Hwang ES, Amon A, Murray AW. Budding yeast Cdc20: a target of the spindle checkpoint. Science 279:1041–1044 (1998).
221. Golsteyn RM, Mundt KE, Fry AM, Nigg EA. Cell cycle regulation of the activity and subcellular localization of PLK1, a human protein kinase implicated in mitotic spindle function. J Cell Biol 129:1617–1628 (1995).
222. Hamanaka R, Smith MR, O'Connor PM, Maloid S, Mihalic K, Spivak JL, Longo DL, Ferris DK. Polo-like kinase is a cell cycle-regulated kinase activated during mitosis. J Biol Chem 270:21086–21091 (1995).
223. Lane HA, Nigg EA. Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J Cell Biol 135:1701–1713 (1996).
224. Descombes P, Nigg EA. The polo-like kinase Plx1 is required for M phase exit and destruction of mitotic regulators in Xenopus egg extracts. EMBO J 17:1328–1335 (1998).
225. Kotani S, Tugendreich S, Fujii M, Jorgensen PM, Watanabe N, Hoog C, Hieter P, Todokoro K. PKA and MPF-activated polo-like kinase regulate anaphase-promoting complex activity and mitosis progression. Mol Cell 1:371–380 (1998).
226. Li Y, Benezra R. Identification of a human mitotic checkpoint gene: hsMAD2. Science 274:246–248 (1996).
227. Cahill DP, Lengauer C, Yu J, Riggins GJ, Willson JKV, Markowitz SD, Kinzler KW, Vogelstein B. Mutations of mitotic checkpoint genes in human cancers. Nature 392:300–303 (1998).
228. Cross SM, Sanchez CA, Morgan CA, Schimke MK, Ramel S, Idzerda RL, Raskind WH, Reid BJ. A p53-dependent mouse spindle checkpoint. Science 267:1353–1356 (1995).
229. Di Leonardo A, Khan SH, Linke SP, Greco V, Seidita G, Wahl GM. DNA rereplication in the presence of mitotic spindle inhibitors in human and mouse fibroblasts lacking either p53 or pRb function. Cancer Res 57:1013–1019 (1997).
230. Lanni JS, Jacks T. Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Mol Cell Biol 18:1055–1064 (1998).
231. Khan SH, Wahl GM. p53 and pRb prevent rereplication in response to microtubule inhibitors by mediating a reversible G_1 arrest. Cancer Res 58:396–401 (1998).
232. Walters RA, Gurley LR, Tobey RA. Effects of caffeine on radiation-induced phenomena associated with cell-cycle traverse of mammalian cells. Biophys J 14:99–118 (1974).
233. Snyder MH, Kimler BF, Leeper DB. The effect of caffeine on radiation-induced division delay. Int J Radiat Biol Relat Stud Phys Chem Med 32:281–284 (1977).
234. Tolmach LJ, Jones RW, Busse PM. The action of caffeine on X-irradiated HeLa cells. I. Delayed inhibition of DNA synthesis. Radiat Res 71:653–65 (1977).

235. Tomasovic SP, Dewey WC. Comparative studies of the effects of drugs on X-ray-induced G_2 delay. Radiat Res 74:112–128 (1978).
236. Schlegel R, Pardee AB. Caffeine-induced uncoupling of mitosis from the completion of DNA replication in mammalian cells. Science 232:1264–1266 (1986).
237. Rowley R. Reduction of radiation-induced G_2 arrest by caffeine. Radiat Res 129:224–227 (1992).
238. Crompton NE, Hain J, Jaussi R, Burkart W. Staurosporine- and radiation-induced G_2-phase cell cycle blocks are equally released by caffeine. Radiat Res 135:372–379 (1993).
239. Fingert HJ, Chang JD, Pardee AB. Cytotoxic, cell cycle, and chromosomal effects of methylxanthines in human tumor cells treated with alkylating agents. Cancer Res 46:2463–2467 (1986).
240. Musk SR, Steel GG. Override of the radiation-induced mitotic block in human tumour cells by methylxanthines and its relationship to the potentiation of cytotoxicity. Int J Radiat Biol 57:1105–1112 (1990).
241. Teicher BA, Holden SA, Herman TS, Epelbaum R, Pardee AB, Dezube B. Efficacy of pentoxifylline as a modulator of alkylating agent activity *in vitro* and *in vivo*. Anticancer Res 11:1555–1560 (1991).
242. Russell KJ, Wiens LW, Demers GW, Galloway DA, Plon SE, Groudine M. Abrogation of the G_2 checkpoint results in differential radiosensitization of G_1 checkpoint-deficient and G_1 checkpoint-competent cells. Cancer Res 55:1639–1642 (1995).
243. Powell SN, Defrank JS, Connell P, Eogan M, Preffer F, Dombkowski D, Tang W, Friend S. Differential sensitivity of p53(-) and p53(+) cells to caffeine-induced radiosensitization and override of G_2 delay. Cancer Res 55:1643–1648 (1995).
244. Lau CC, Pardee AB. Mechanism by which caffeine potentiates lethality of nitrogen mustard. Proc Natl Acad Sci USA 79:2942–2946 (1982).
245. Boder E, Sedgwick RP. *Ataxia-telangiectasia*. (Clinical and immunological aspects). Psychiatr Neurol Med Psychol Beih 14:8–16 (1970).
246. Boder E. *Ataxia-telangiectasia*: an overview. Kroc Found Ser 19:1–63 (1985).
247. Sedgwick RP, Boder E. *Ataxia-telangiectasia*. In: Handbook of Clinical Neurology. Vol 6 (Vinkins PJ, Bruyn GW, Klawans HL, eds). New York:Elsevier Science Publishers B.V., 1991;347–423.
248. Swift M, Morrell D, Massey RB, Chase CL. Incidence of cancer in 161 families affected by *Ataxia-telangiectasia*. N Engl J Med 325:1831–6 (1991).
249. Meyn MS. High spontaneous intrachromosomal recombination rates in *Ataxia-telangiectasia*. Science 260:1327–1330 (1993).
250. Easton DF. Cancer risks in A-T heterozygotes. Int. J Radiat Biol 66:S177–S182 (1994).
251. Shiloh Y, Tabor E, Becker Y. Colony-forming ability of *Ataxia-telangiectasia* skin fibroblasts is an indicator of their early senescence and increased demand for growth factors. Exp Cell Res 140:191–199 (1982).
252. Scott D, Spreadborough AR, Roberts SA. Radiation-induced G_2 delay and spontaneous chromosome aberrations in *Ataxia-telangiectasia* homozygotes and heterozygotes. Int J Radiat Biol 66:S157–S163 (1994).
253. Gatti RA, Berkel I, Boder E, Braedt G, Charmley P, Concannon P, Ersoy F, Foroud T, Jaspers NG, Lange K, et al. Localization of an *Ataxia-telangiectasia* gene to chromosome 11q22–23. Nature 336:577–580 (1988).
254. McKinnon PJ. *Ataxia-telangiectasia*: an inherited disorder of ionizing-radiation sensitivity in man. Hum Genet 75:197–208 (1987).
255. Savitsky K, Barshira A, Gilad S, Rotman G, Ziv Y, Vanagaite L, Tagle DA, Smith S, Uziel T, Sfez S, et al. A single *Ataxia telangiectasia* gene with a product similar to PI-3 kinase. Science 268:1749–1753 (1995).
256. Savitsky K, Sfez S, Tagle DA, Ziv Y, Sartiel A, Collins FS, Shiloh Y, Rotman G. The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species. Hum Mol Genet 4:2025–2032 (1995).
257. Canman CE, Lim DS, Cimprich KA, Taya Y, Tamai K, Sakaguchi K, Appella E, Kastan MB, Siliciano JD. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281:1677–1679 (1998).
258. Banin S, Moyal L, Shieh SY, Taya Y, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y, Ziv Y. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281:1674–1677 (1998).
259. Rotman G, Shiloh Y. *Ataxia-telangiectasia*: is ATM a sensor of oxidative damage and stress? Bioessays 19:911–917 (1997).
260. Khanna KK, Lavin MF. Ionizing radiation and UV induction of p53 protein by different pathways in *Ataxia-telangiectasia* cells. Oncogene 8:3307–3312 (1993).
261. Canman CE, Wolff AC, Chen CY, Fornace AJ, Kastan MB. The p53-dependent G_1 cell cycle checkpoint pathway and *Ataxia-telangiectasia*. Cancer Res 54:5054–5058 (1994).
262. Edwards MJ, Taylor AMR. Unusual levels of $(ADP\text{-}ribose)_n$ and DNA synthesis in *Ataxia telangiectasia* cells following γ-ray irradiation. Nature 287:745–747 (1980).
263. Houldsworth J, Lavin MF. Effect of ionizing radiation on DNA synthesis in *Ataxia telangiectasia* cells. Nucleic Acids Res 8:3709–3720 (1980).
264. Xie GF, Habbersett RC, Jia YW, Peterson SR, Lehnert BE, Bradbury EM, Danna JA. Requirements for p53 and the ATM gene product in the regulation of G1/S and S phase checkpoints. Oncogene 16:721–736 (1998).
265. Lehman AR, Stevens S. The production and repair of double strand breaks in cells from normal humans and from patients with *Ataxia telangiectasia*. Biochim Biophys Acta 474:49–60 (1977).
266. Fornace AJ Jr, Little JB. Normal repair of DNA single-strand breaks in patients with *Ataxia telangiectasia*. Biochim Biophys Acta 607: 432–437 (1980).
267. Ward AJ, Olive PL, Burr AH, Rosin MP. Response of fibroblast cultures from *Ataxia-telangiectasia* patients to reactive oxygen species generated during inflammatory reactions. Environ Mol Mutagen 24:103–111 (1994).
268. Taylor AM. Unrepaired DNA strand breaks in irradiated *Ataxia telangiectasia* lymphocytes suggested from cytogenetic observations. Mutat Res 50:407–418 (1978).
269. Cornforth MN, Bedford JS. On the nature of a defect in cells from individuals with *Ataxia-telangiectasia*. Science 227:1589–1591 (1985).
270. Parshad R, Sanford KK, Jones GM. Chromosomal radiosensitivity during the G_2 cell-cycle period of skin fibroblasts from individuals with familial cancer. Proc Natl Acad Sci USA 82:5400–5403 (1985).
271. Pandita TK, Hittelman WN. The contribution of DNA and chromosome repair deficiencies to the radiosensitivity of *Ataxia-telangiectasia*. Radiat Res 131:214–223 (1992).
272. Hittelman WN, Pandita TK. Possible role of chromatin alteration in the radiosensitivity of *Ataxia-telangiectasia*. Int J Radiat Biol 66:S109–S113 (1994).
273. Mitchell ELD, Scott D. G_2 chromosomal radiosensitivity in fibroblasts of *Ataxia-telangiectasia* heterozygotes and a Li-Fraumeni Syndrome patient with radioresistant cells. Int J Radiat Biol 72:435–438 (1997).
274. Shiloh Y, Tabor E, Becker Y. Abnormal response of *aAtaxia-telangiectasia* cells to agents that break the deoxyribose moiety of DNA via a targeted free radical mechanism. Carcinogenesis 4:1317–1322 (1983).
275. Dar ME, Winters TA, Jorgensen TJ. Identification of defective illegitimate recombinational repair of oxidatively-induced DNA double-strand breaks in *Ataxia-telangiectasia* cells. Mutat Res 384:169–179 (1997).
276. Vuillaume M. Reduced oxygen species, mutation, induction and cancer initiation. Mutat Res 186:43–72 (1987).
277. Meredith MJ, Dodson ML. Imparied glutathione biosynthesis in cultured human *Ataxia-telangiectasia* cells. Cancer Res 47:4576–4581 (1987).
278. Vuillaume M, Best-Belpomme M, Lafont R, Hubert M, Decroix Y, Sarasin A. Stimulated production of ATP by H_2O_2 disproportionation in extracts from normal and *Xeroderma pigmentosum* skins, and from normal, *Xeroderma pigmentosum*, *Ataxia telangiectasia* and simian virus 40 transformed cell lines. Carcinogenesis 10:1375–1381 (1989).
279. Green MHL, Marcovitch AJ, Harcourt SA, Lowe JE, Green IC, Arlett CF. Hypersensitivity of ataxia-telangiectasia fibroblasts to a nitric oxide donor. Free Radic Biol Med 22:343–347 (1997).
280. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820–823 (1971).
281. Knudson AG Jr. Hereditary cancers disclose a class of cancer genes. Cancer 63:1888–1891 (1989).
282. Weichselbaum RR, Beckett M, Diamond A. Some retinoblastomas, osteosarcomas, and soft tissue sarcomas may share a common etiology. Proc Natl Acad Sci USA 85:2106–2109 (1988).
283. Lee WH, Bookstein R, Hong F, Young LJ, Shew JY, Lee EY. Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science 235:1394–1399 (1987).
284. Weintraub SJ. Inactivation of tumor suppressor proteins in lung cancer. Am J Respir Cell Mol Biol 15:150–155 (1996).
285. Harbour JW, Lai SL, Whang Peng J, Gazdar AF, Minna JD, Kaye FJ. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 241:353–357 (1988).
286. Lee EY, To H, Shew JY, Bookstein R, Scully P, Lee WH. Inactivation of the retinoblastoma susceptibility gene in human breast cancers. Science 241:218–221 (1988).
287. Grossman HB, Liebert M, Antelo M, Dinney CP, Hu SX, Palmer JL, Benedict WF. p53 and RB

expression predict progression in T1 bladder cancer. Clin Cancer Res 4:829–834 (1998).
288. Cote RJ, Dunn MD, Chatterjee SJ, Stein JP, Shi SR, Tran QC, Hu SX, Xu HJ, Groshen S, Taylor CR, et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 58:1090–1094 (1998).
289. Ishikawa J, Xu HJ, Hu SX, Yandell DW, Maeda S, Kamidono S, Benedict WF, Takahashi R. Inactivation of the retinoblastoma gene in human bladder and renal cell carcinomas. Cancer Res 51:5736–5743 (1991).
290. Sanders BM, Jay M, Draper GJ, Roberts EM. Non-ocular cancer in relatives of retinoblastoma patients. Br J Cancer 60:358–365 (1989).
291. Lee EY, Chang CY, Hu N, Wang YC, Lai CC, Herrup K, Lee WH, Bradley A. Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature 359:288–294 (1992).
292. Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA. Effects of an Rb mutation in the mouse. Nature 359:295–300 (1992).
293. Hu N, Gutsmann A, Herbert DC, Bradley A, Lee WH, Lee EY. Heterozygous Rb-1 delta 20/+mice are predisposed to tumors of the pituitary gland with a nearly complete penetrance. Oncogene 9:1021–1027 (1994).
294. White AE, Livanos EM, Tlsty TD. Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins. Genes Dev 8:666–677 (1994).
295. Almasan A, Linke SP, Paulson TG, Huang LC, Wahl GM. Genetic instability as a consequence of inappropriate entry into and progression through S-phase. Cancer Metastasis Rev 14:59–73 (1995).
296. Reznikoff CA, Belair C, Savelieva E, Zhai Y, Pfeifer K, Yeager T, Thompson KJ, DeVries S, Bindley C, Newton MA, et al. Long-term genome stability and minimal genotypic and phenotypic alterations in HPV16 E7-, but not E6-immortalized human uroepithelial cells. Genes Dev 8:2227–2240 (1994).
297. Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Annu Intern Med 71:747–752 (1969).
298. Li FP, Fraumeni JF Jr, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW. A cancer family syndrome in twenty-four kindreds. Cancer Res 48:5358–5362 (1988).
299. Garber JE, Goldstein AM, Kantor AF, Dreyfus MG, Fraumeni JF, Jr., Li FP. Follow-up study of twenty-four families with Li-Fraumeni syndrome. Cancer Res 51:6094–6097 (1991).
300. Varley JM, Evans DG, Birch JM. Li-Fraumeni syndrome—a molecular and clinical review. Br J Cancer 76:1–14 (1997).
301. Malkin D, Li FP, Strong LC, Fraumeni JF, Jr., Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233–1238 (1990).
302. Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 348:747–749 (1990).
303. Varley JM, McGown G, Thorncroft M, Santibanez-Koref MF, Kelsey AM, Tricker KJ, Evans DG, Birch JM. Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. Cancer Res 57:3245–3252 (1997).
304. Bischoff F, Yim SO, Pathak S, Grant G, Siciliano MJ, Giovanella BC, Strong LC, Tainsky MA. Spontaneous abnormalities in normal fibroblasts from patients with Li-Fraumeni cancer syndrome: aneuploidy and immortalization. Cancer Res 50:7979–7984 (1990).
305. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89:7491–7495 (1992).
306. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70:923–935 (1992).
307. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70:937–948 (1992).
308. Parshad R, Price FM, Pirollo KF, Chang EH, Sanford KK. Cytogenetic response to G_2-phase X irradiation in relation to DNA repair and radiosensitivity in a cancer-prone family with Li-Fraumeni syndrome. Radiat Res 136:236–240 (1993).
309. Yonish-Rouach E, Grunwald D, Wilder S, Kimchi A, May E, Lawrence JJ, May P, Oren M. p53-mediated cell death: relationship to cell cycle control. Mol Cell Biol 13:1415–1423 (1993).
310. Rogan EM, Bryan TM, Hukku B, Maclean K, Chang AC, Moy EL, Englezou A, Warneford SG, Dalla-Pozza L, Reddel RR. Alterations in p53 and p16INK4 expression and telomere length during spontaneous immortalization of Li-Fraumeni syndrome fibroblasts. Mol Cell Biol 15:4745–4753 (1995).
311. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Butel JS, Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature (Lond) 356:215–221 (1992).
312. Harvey M, McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A, Donehower LA. Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat Genet 5:225–229 (1993).
313. Kemp CJ, Wheldon T, Balmain A. p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nat Genet 8:66–69 (1994).
314. Oren M. p53: the ultimate tumor suppressor gene? FASEB J 6:3169–3176 (1992).
315. O'Connor PM, Jackman J, Jondle D, Bhatia K, Magrath I, Kohn KW. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitts lymphoma cell lines. Cancer Res 53:4776–4780 (1993).
316. Srivastava S, Wang S, Tong YA, Hao ZM, Chang EH. Dominant negative effect of a germ-line mutant p53: a step fostering tumorigenesis. Cancer Res 53:4452–4455 (1993).
317. Unger T, Mietz JA, Scheffner M, Yee CL, Howley PM. Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition, and transformation suppression. Mol Cell Biol 13:5186–5194 (1993).
318. Bowman T, Symonds H, Gu L, Yin C, Oren M, Van Dyke T. Tissue-specific inactivation of p53 tumor suppression in the mouse. Genes Dev 10:826–835 (1996).
319. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 88:323–331 (1997).
320. Varghese AJ, Wang SY. Thymine-thymine adduct as a photoproduct of thymine. Science 160:186–187 (1968).
321. Varghese AJ, Patrick MH. Cytosine derived heteroadduct formation in ultraviolet-irradiated DNA. Nature 223:299–300 (1969).
322. Varghese AJ. Photochemistry of nucleic acids and their constituents. Photophysiology 7:207–274 (1972).
323. Lober G, Kittler L. Selected topics in photochemistry of nucleic acids. Recent results and perspectives. Photochem Photobiol 25:215–233 (1977).
324. Tyrrell RM. UV activation of mammalian stress proteins. EXS 77:255–271 (1996).
325. Tyrrell RM. Activation of mammalian gene expression by the UV component of sunlight — from models to reality. Bioessays 18:139–148 (1996).
326. Black HS, de Gruijl FR, Forbes PD, Cleaver JE, Ananthaswamy HN, de Fabo EC, Ullrich SE, Tyrrell RM. Photocarcinogenesis: an overview. J Photochem Photobiol B 40:29–47 (1997).
327. Kvam E, Tyrrell RM. Induction of oxidative DNA base damage in human skin cells by UV and near visible radiation. Carcinogenesis 18:2379–2384 (1997).
328. Setlow RB. Cyclobutane-type pyrimidine dimers in polynucleotides. Science 153:379–386 (1966).
329. Setlow RB, Carrier WL. Pyrimidine dimers in ultraviolet-irradiated DNA's. J Mol Biol 17:237–254 (1966).
330. Setlow RB. The photochemistry, photobiology, and repair of polynucleotides. Prog Nucleic Acid Res Mol Biol. 8:257–295 (1968).
331. Liu M, Pelling JC. UV-B/A irradiation of mouse keratinocytes results in p53-mediated WAF1/CIP1 expression. Oncogene 10:1955–1960 (1995).
332. Kaufmann WK. Pathways of human cell post-replication repair. Carcinogenesis 10:1–11 (1989).
333. Cordeiro-Stone M, Zaritskaya LS, Price LK, Kaufmann WK. Replication fork bypass of a pyrimidine dimer blocking leading strand DNA synthesis. J Biol Chem 272:13945–13954 (1997).
334. Rosette C, Karin M. Ultraviolet light and osmotic stress: activation of the JNK cascade through multiple growth factor and cytokine receptors. Science 274:1194–1197 (1996).
335. Roddey PK, Garmyn M, Park HY, Bhawan J, Gilchrest BA. Ultraviolet irradiation induces c-*fos* but not c-Ha-*ras* proto-oncogene expression in human epidermis. J Invest Dermatol 102:296–299 (1994).
336. Matsui MS, DeLeo VA. Induction of protein kinase C activity by ultraviolet radiation. Carcinogenesis 11:229–234 (1990).
337. Yarosh DB, Kripke ML. DNA repair and cytokines in antimutagenesis and anticarcinogenesis. Mutat Res 350:255–260 (1996).
338. Scotto J, Fears TR. The association of solar ultraviolet and skin melanoma incidence among Caucasians in the United States. Cancer Invest 5:275–283 (1987).
339. Dalziel KL. Aspects of cutaneous ageing. Clin Exp Dermatol 16:315–323 (1991).
340. Kricker A, Armstrong BK, English DR. Sun exposure and non-melanocytic skin cancer. Cancer Causes Control 5:367–392 (1994).
341. English DR, Armstrong BK, Kricker A, Fleming C. Sunlight and cancer. Cancer Causes Control 8:271–283 (1997).

342. Grossman D, Leffell DJ. The molecular basis of nonmelanoma skin cancer: new understanding. Arch Dermatol 133:1263–1270 (1997).
343. Yarosh D, Alas LG, Yee V, Oberyszyn A, Kibitel JT, Mitchell D, Rosenstein R, Spinowitz A, Citron M. Pyrimidine dimer removal enhanced by DNA repair liposomes reduces the incidence of UV skin cancer in mice. Cancer Res 52:4227–4231 (1992).
344. Cleaver JE. Defective repair replication of DNA in *Xeroderma pigmentosum*. Nature 218:652–656 (1968).
345. Cleaver JE. *Xeroderma pigmentosum*: a human disease in which an initial stage of DNA repair is defective. Proc Natl Acad Sci USA 63:428–435 (1969).
346. Setlow RB, Regan JD, German J, Carrier WL. Evidence that *Xeroderma pigmentosum* cells do not perform the first step in the repair of ultraviolet damage to their DNA. Proc Natl Acad Sci USA 64:1035–1041 (1969).
347. Pawsey SA, Magnus IA, Ramsay CA, Benson PF, Giannelli F. Clinical, genetic and DNA repair studies on a consecutive series of patients with *Xeroderma pigmentosum*. Q J Med 48:179–210 (1979).
348. Kaufmann WK, Cleaver JE. Mechanisms of inhibition of DNA replication by ultraviolet light in normal human and *Xeroderma pigmentosum* fibroblasts. J Mol Biol 149:171–187 (1981).
349. Timme TL, Moses RE. Diseases with DNA damage-processing defects. Am J Med Sci 295:40–48 (1988).
350. Weeda G, van Ham RC, Vermeulen W, Bootsma D, van der Eb AJ, Hoeijmakers JH. A presumed DNA helicase encoded by ERCC-3 is involved in the human repair disorders *Xeroderma pigmentosum* and Cockayne's syndrome. Cell 62:777–791 (1990).
351. Tanaka K, Miura N, Satokata I, Miyamoto I, Yoshida MC, Satoh Y, Kondo S, Yasui A, Okayama H, Okada Y. Analysis of a human DNA excision repair gene involved in group A *Xeroderma pigmentosum* and containing a zinc-finger domain. Nature 348:73–76 (1990).
352. Boyer JC, Kaufmann WK, Brylawski BP, Cordeiro-Stone M. Defective postreplication repair in *Xeroderma pigmentosum* variant fibroblasts. Cancer Res 50:2593–2598 (1990).
353. Bootsma D, Hoeijmakers JH. The genetic basis of *Xeroderma pigmentosum*. Ann Genet 34:143–150 (1991).
354. Legerski R, Peterson C. Expression cloning of a human DNA repair gene involved in *Xeroderma pigmentosum* group C. Nature 359:70–73 (1992).
355. Schaeffer L, Roy R, Humbert S, Moncollin V, Vermeulen W, Hoeijmakers JH, Chambon P, Egly JM. DNA repair helicase: a component of BTF2 (TFIIH) basic transcription factor. Science 260:58–63 (1993).
356. Wang XW, Vermeulen W, Coursen JD, Gibson M, Lupold SE, Forrester K, Xu G, Elmore L, Yeh H, Hoeijmakers JH, et al. The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes Dev 10:1219–1232 (1996).
357. Cleaver JE, States JC. The DNA damage-recognition problem in human and other eukaryotic cells: the XPA damage binding protein. Biochem J 328:1–12 (1997).
358. Sands AT, Abuin A, Sanchez A, Conti CJ, Bradley A. High susceptibility to ultraviolet-induced carcinogenesis in mice lacking XPC. Nature 377:162–165 (1995).
359. Nakane H, Takeuchi S, Yuba S, Saijo M, Nakatsu Y, Murai H, Nakatsuru Y, Ishikawa T, Hirota S, Kitamura Y, et al. High incidence of ultraviolet-B-or chemical-carcinogen-induced skin tumours in mice lacking the *Xeroderma pigmentosum* group A gene. Nature 377:165–168 (1995).
360. de Vries A, van Oostrom CTM, Hofhuis FMA, Dortant PM, Berg RJW, de Gruijl FR, Wester PW, van Kreijl CF, Capel PJA, van Steeg H, et al. Increased susceptibility to ultraviolet-B and carcinogens of mice lacking the DNA excision repair gene XPA. Nature 377:169–173 (1995).
361. Muller HJ. Artificial transmutation of the gene. Science 66:84–87 (1927).
362. Cerutti PA. DNA base damage induced by ionizing radiation. In: Photochemistry and Photobiology of Nucleic Acids (Wang SY, ed). New York: Academic Press, 1976;375–401.
363. Shellabarger CJ. Radiation carcinogenesis: laboratory studies. Cancer 37:1090–1096 (1976).
364. Tokunaga M, Norman JE Jr, Asano M, Tokuoka S, Ezaki H, Nishimori I, Tsuji Y. Malignant breast tumors among atomic bomb survivors, Hiroshima and Nagasaki, 1950–74. J Natl Cancer Inst 62:1347–1359 (1979).
365. Hutchinson F. Chemical changes induced in DNA by ionizing radiation. Prog Nucleic Acid Res Mol Biol 32:115–154 (1985).
366. Goodhead DT. The initial physical damage produced by ionizing radiations. Int. J Radiat Biol 56:623–634 (1989).
367. Nikjoo H, O'Neill P, Terrissol M, Goodhead DT. Modelling of radiation-induced DNA damage: the early physical and chemical event. Int J Radiat Biol 66:453–457 (1994).
368. Goodhead DT. Initial events in the cellular effects of ionizing radiations: clustered damage in DNA. Int J Radiat Biol 65:7–17 (1994).
369. Morgan WF, Day JP, Kaplan MI, McGhee EM, Limoli CL. Genomic instability induced by ionizing radiation. Radiat Res 146:247–258 (1996).
370. Shimizu Y, Kato H, Schull WJ. Risk of cancer among atomic bomb survivors. J Radiat Res 2:54–63 (1991).
371. Otake M, Schull WJ, Lee S. Threshold for radiation-related severe mental retardation in prenatally exposed A-bomb survivors: a re-analysis. Int J Radiat Biol 70:755–763 (1996).
372. Blot WJ. Growth and development following prenatal and childhood exposure to atomic radiation. J Radiat Res Tokyo 16:82–88 (1975).
373. Skov KA. The contribution of hydroxyl radical to radiosensitization: a study of DNA damage. Radiat Res 99:502–510 (1984).
374. Teoule R. Radiation-induced DNA damage and its repair. Int J Radiat Biol 51:573–589 (1987).
375. Ward JF. DNA damage produced by ionizing radiation in mammalian cells: identities, mechanisms of formation, and reparability. Prog Nucleic Acid Res Mol Biol 35:95–125 (1988).
376. Adams GED. Radiation carcinogenesis. In: Introduction to the Cellular and Molecular Biology of Cancer (Franks LM, Teich N, eds). New York:Oxford University Press, 1986; 154–175.
377. Riley PA. Free radicals in biology: oxidative stress and the effects of ionizing radiation. Int J Radiat Biol 65:27–33 (1994).
378. Jostes RF. Genetic, cytogenetic, and carcinogenic effects of radon: a review. Mutat Res 340:125–139 (1996).
379. Little JB. What are the risks of low-level exposure to alpha radiation from radon? Proc Natl Acad Sci USA 94:5996–5997 (1997).
380. van Hoff J, Averkin YI, Hilchenko EI, Prudyvus IS. Epidemiology of childhood cancer in Belarus: review of data 1978–1994, and discussion of the new Belarusian Childhood Cancer Registry. Stem Cells 2:231–241 (1997).
381. Sohrabi M. The state-of-the-art on worldwide studies in some environments with elevated naturally occurring radioactive materials (NORM). Appl Radiat Isot 49:169–188 (1998).
382. Chen Q, Ames BN. Senescence-like growth arrest induced by hydrogen peroxide in human diploid fibroblast F65 cells. Proc Natl Acad Sci USA 91:4130–4134 (1994).
383. Russo T, Zambrano N, Esposito F, Ammendola R, Cimino F, Fiscella M, Jackman J, O'Connor PM, Anderson CW, Appella E. A p53-independent pathway for activation of WAF1/CIP1 expression following oxidative stress. J Biol Chem 270:29386–29391 (1995).
384. Chen QM, Bartholomew JC, Campisi J, Acosta M, Reagan JD, Ames BN. Molecular analysis of H_2O_2-induced senescent-like growth arrest in normal human fibroblasts: p53 and Rb control G_1 arrest but not cell replication. Biochem J 332:43–50 (1998).
385. Harman DJ. Aging: a theory based on free radical and radiation chemistry. Gerontology 11:298–300 (1956).
386. Floyd RA. Role of oxygen free radicals in carcinogenesis and brain ischemia. FASEB J 4:2587–2597 (1990).
387. Janssen YM, Van Houten B, Borm PJ, Mossman BT. Cell and tissue responses to oxidative damage. Lab Invest 69:261–274 (1993).
388. Ames BN, Shigenaga MK. Oxidants are a major contributor to aging. Ann NY Acad Sci 663:85–96 (1992).
389. Martin GM, Austad SN, Johnson TE. Genetic analysis of ageing: role of oxidative damage and environmental stresses. Nat Genet 13:25–34 (1996).
390. Sohal RS, Weindruch R. Oxidative stress, caloric restriction, and aging. Science 273:59–63 (1996).
391. Breimer LH. Molecular mechanisms of oxygen radical carcinogenesis and mutagenesis: the role of DNA base damage. Mol Carcinog 3:188–197 (1990).
392. Forman HJ, Boveris A. Superoxide radical and hydrogen peroxide in mitochondria. In: Free Radicals in Biology (Pryor E, ed). New York: Academic Press, 1982;65–90.
393. Dizdaroglu M, Rao G, Halliwell B, Gajewski E. Damage to the DNA bases in mammalian chromatin by hydrogen peroxide in the presence of ferric and cupric ions. Arch Biochem Biophys 285:317–324 (1991).
394. Imlay JA, Chin SM, Linn S. Toxic DNA damage by hydrogen peroxide through the Fenton reaction *in vivo* and *in vitro*. Science 240:640–642 (1988).
395. Michalik V, Maurizot MS, Charlier M. Calculation of hydroxyl radical attack on different forms of DNA. J Biomol Struct Dyn 13:565–575 (1995).
396. Keyer K, Imlay JA. Superoxide accelerates DNA damage by elevating free-iron levels. Proc Natl Acad Sci USA 93:13635–13640 (1996).

397. Malins DC, Holmes EH, Polissar NL, Gunselman SJ. The etiology of breast cancer. Characteristic alteration in hydroxyl radical-induced DNA base lesions during oncogenesis with potential for evaluating incidence risk. Cancer 71:3036–3043 (1993).
398. Senturker S, Karahalil B, Inal M, Yilmaz H, Muslumanoglu H, Gedikoglu G, Dizdaroglu M. Oxidative DNA base damage and antioxidant enzyme levels in childhood acute lymphoblastic leukemia. FEBS Lett 416:286–290 (1997).
399. Pryor WA. Cigarette smoke radicals and the role of free radicals in chemical carcinogenicity. Environ Health Perspect 4:875–882 (1997).
400. Erhardt JG, Lim SS, Bode JC, Bode C. A diet rich in fat and poor in dietary fiber increases the *in vitro* formation of reactive oxygen species in human feces. J Nutr 127:706–709 (1997).
401. Thome J, Zhang J, Davids E, Foley P, Weijers HG, Wiesbeck GA, Boning J, Riederer P, Gerlach M. Evidence for increased oxidative stress in alcohol-dependent patients provided by quantification of *in vivo* salicylate hydroxylation products. Alcohol Clin Exp Res 21:82–85 (1997).
402. Valavanidis A, Balomenou H, Macropoulou I, Zarodimos I. A study of the synergistic interaction of asbestos fibers with cigarette tar extracts for the generation of hydroxyl radicals in aqueous buffer solution. Free Radic Biol Med 20:853–858 (1996).
403. Nagata C, Kodama M, Ioki Y, Kimura T. Free radicals produced from chemical carcinogens and their signifance in carcinogenesis. In: Free Radicals and Cancer (Floyd RA, ed). New York:Marcel Dekker, 1982;1–62.
404. Moran LA, Scrimgeour KG, Horton HR, Ochs RS, Rawn JD. Biochemistry. Englewood Cliffs, NJ:Neil Patterson Publishers, 1995;1824–1825.
405. Skulachev VP. Aging is a specific biological function rather than the result of a disorder in complex living systems: biochemical evidence in support of Weismann's hypothesis. Biochemistry (Mosc) 62:1191–1195 (1997).
406. Mello-Filho AC, Meneghini R. *In vivo* formation of single-strand breaks in DNA by hydrogen peroxide is mediated by the Haber-Weiss reaction. Biochim Biophys Acta 781:56–63 (1984).
407. Chance B, Sies H, Boveris A. Hydroperoxide metabolism in mammalian organs. Physiol Rev 59:527–605 (1979).
408. Parkes TL, Elia AJ, Dickinson D, Hilliker AJ, Phillips JP, Boulianne GL. Extension of *Drosophila* lifespan by overexpression of human SOD1 in motorneurons. Nat Genet 19:171–174 (1998).
409. Nathan C, Xie QW. Nitric oxide synthases: roles, tolls, and controls. Cell 78:915–918 (1994).
410. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 87:1620–1624 (1990).
411. Yoshie Y, Ohshima H. Synergistic induction of DNA strand breakage by cigarette tar and nitric oxide. Carcinogenesis 18:1359–1363 (1997).
412. O'Connor PM, Ferris DK, White GA, Pines J, Hunter T, Longo DL, Kohn KW. Relationships between cdc2 kinase, DNA cross-linking, and cell cycle perturbations induced by nitrogen mustard. Cell Growth Differ 3:43–52 (1992).
413. Allday MJ, Inman GJ, Crawford DH, Farrell PJ. DNA damage in human B cells can induce apoptosis, proceeding from G_1/S when p53 is transactivation competent and G_2/M when it is transactivation defective. EMBO J 14:4994–5005 (1995).
414. Fan SJ, Smith ML, Rivet DJ, Duba D, Zhan QM, Kohn KW, Fornace AJ, O'Connor PM. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 55:1649–1654 (1995).
415. Ceraline J, Deplanque G, Duclos B, Limacher JM, Vincent F, Goldblum S, Bergerat JP. Relationships between p53 induction, cell cycle arrest and survival of normal human fibroblasts following DNA damage. Bull Cancer 84:1007–1016 (1997).
416. Fan SJ, Chang JK, Smith ML, Duba D, Fornace AJ, O'Connor PM. Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard. Oncogene 14:2127–2136 (1997).
417. Huang TS, Kuo ML, Shew JY, Chou YW, Yang WK. Distinct p53-mediated G_1/S checkpoint responses in two NIH3T3 subclone cells following treatment with DNA-damaging agents. Oncogene 13:625–632 (1996).
418. Longhese MP, Neecke H, Paciotti V, Lucchini G, Plevani P. The 70 kDa subunit of replication protein A is required for the G_1/S and intra-S DNA damage checkpoints in budding yeast. Nucleic Acids Res 24:3533–3537 (1996).
419. Hawn MT, Umar A, Carethers JM, Marra G, Kunkel TA, Boland CR, Koi M. Evidence for a connection between the mismatch repair system and the G_2 cell cycle checkpoint. Cancer Res 55:3721–3725 (1995).
420. Albert RE, Burns FJ. Carcinogenic atmospheric pollutants and the nature of low-level risks. In: Origins of Human Cancer (Hiatt HH, Watson JD, Winston JA, eds). Cold Spring Harbor, NY:Cold Spring Harbor Laboratory Press, 1977;289–292.
421. Doll R. Pott and the path to prevention. Arch Geschwulstforsch 45:521–531 (1975).
422. Phillips DH. Fifty years of benzo(a)pyrene. Nature 303:468–472 (1983).
423. Gelboin HV. Carcinogens, enzyme induction, and gene action. Adv Cancer Res 10:1–81 (1967).
424. Wood AW, Levin W, Lu AY, Yagi H, Hernandez O, Jerina DM, Conney AH. Metabolism of benzo(a)pyrene and benzo (a)pyrene derivatives to mutagenic products by highly purified hepatic microsomal enzymes. J Biol Chem 251: 4882–4890 (1976).
425. Marquardt H, Grover PL, Sims P. *In vitro* malignant transformation of mouse fibroblasts by non-K-region dihydrodiols derived from 7-methylbenz(a)anthracene, 7,12-dimethylbenz(a)-anthracene, and benzo(a)pyrene. Cancer Res 36:2059–2064 (1976).
426. Buening MK, Wislocki PG, Levin W, Yagi H, Thakker DR, Akagi H, Koreeda M, Jerina DM, Conney AH. Tumorigenicity of the optical enantiomers of the diastereomeric benzo[a]pyrene 7,8-diol-9,10-epoxides in newborn mice: exceptional activity of (+)-7β,8α-dihydroxy-9α,10α-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene. Proc Natl Acad Sci USA 75:5358–5361 (1978).
427. Kapitulnik J, Wislocki PG, Levin W, Yagi H, Jerina DM, Conney AH. Tumorigenicity studies with diol-epoxides of benzo(a)pyrene which indicate that (+/-)-*trans*-7β,8α-dihydroxy-9α,10α-epoxy-7,8,9,10-tetrahydrobenzo(a)pyrene is an ultimate carcinogen in newborn mice. Cancer Res 38:354–358 (1978).
428. Weinstein IB, Jeffrey AM, Jennette KW, Blobstein SH, Harvey RG, Harris C, Autrup H, Kasai H, Nakanishi K. Benzo(a)pyrene diol epoxides as intermediates in nucleic acid binding *in vitro* and *in vivo*. Science 193:592–595 (1976).
429. Chen L, Devanesan PD, Higginbotham S, Ariese F, Jankowiak R, Small GJ, Rogan EG, Cavalieri EL. Expanded analysis of benzo[a]pyrene-DNA adducts formed *in vitro* and in mouse skin: their significance in tumor initiation. Chem Res Toxicol 9:897–903 (1996).
430. Cavalieri EL, Rogan EG. Central role of radical cations in metabolic activation of polycyclic aromatic hydrocarbons. Xenobiotica 25:677–688 (1995).
431. Hsu IC, Bowden GT, Harris CC. A comparison of cytotoxicity, ouabain-resistant mutation, sister-chromatid exchanges, and nascent DNA synthesis in Chinese hamster cells treated with dihydrodiol epoxide derivatives of benzo[a]pyrene. Mutat Res 63:351–359 (1979).
432. Kaufmann WK, Boyer JC, Smith BA, Cordeiro Stone M. DNA repair and replication in human fibroblasts treated with (+/-)-*r*-7,*t*-8-dihydroxy-*t*-9,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene. Biochim Biophys Acta 824:146–151 (1985).
433. Cordeiro-Stone M, Boyer JC, Smith BA, Kaufmann WK. Effect of benzo[a]pyrene-diol-epoxide-I on growth of nascent DNA in synchronized human fibroblasts. Carcinogenesis 7:1775–1781 (1986).
434. Yamanishi DT, Bowden GT, Cress AE. An analysis of DNA replication in synchronized CHO cells treated with benzo[a]pyrene diol epoxide. Biochim Biophys Acta 910:34–42 (1987).
435. Paules RS, Cordeiro-Stone M, Mass MJ, Poirier MC, Yuspa SH, Kaufman DG. Benzo[alpha]pyrene diol epoxide I binds to DNA at replication forks. Proc Natl Acad Sci USA 85:2176–2180 (1988).
436. Black KA, McFarland RD, Grisham JW, Smith GJ. S-phase block and cell death in human lymphoblasts exposed to benzo[a]pyrene diol epoxide or N-acetoxy-2-acetylaminofluorene. Toxicol Appl Pharmacol 97:463–472 (1989).
437. Kaufmann WK. Cell cycle checkpoints and DNA repair preserve the stability of the human genome. Cancer Metastasis Rev 14:31–41 (1995).
438. Yang LL, Maher VM, McCormick JJ. Relationship between excision repair and the cytotoxic and mutagenic effect of the 'anti' 7,8-diol-9,10-epoxide of benzo[a]pyrene in human cells. Mutat Res 94:435–447 (1982).
439. Yang JL, Maher VM, McCormick JJ. Kinds of mutations formed when a shuttle vector containing adducts of (+/-)-7 β, 8 α-dihydroxy-9 α, 10 α-epoxy-7,8,9, 10-tetrahydrobenzo[a]pyrene replicates in human cells. Proc Natl Acad Sci USA 84:3787–3791 (1987).
440. Yang JL, Chen RH, Maher VM, McCormick JJ. Kinds and location of mutations induced by (+/-)-7 β,8 α-dihydroxy-9 α,10 α-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene in the coding region of the hypoxanthine (guanine) phosphoribosyltransferase gene in diploid human fibroblasts. Carcinogenesis 12:71–75 (1991).
441. Wu X, Zhao Y, Honn SE, Tomlinson GE, Minna JD, Hong WK, Spitz MR. Benzo[a]pyrene diol epoxide-induced 3p21.3 aberrations and genetic predisposition to lung cancer. Cancer Res 58:1605–1608 (1998).

442. Groopman JD, Cain LG. Interactions of fungal and plant toxins with DNA: aflatoxins, sterigmacystin, safrole, cycasin, and pyrrolizidine alkaloids. In: Chemical Carcinogenesis and Mutagenesis I (Cooper CS, Grover PL, eds). Berlin:Springer-Verlag, KG, 1990;373–407.
443. Layton DW, Bogen KT, Knize MG, Hatch FT, Johnson VM, Felton JS. Cancer risk of heterocyclic amines in cooked foods: an analysis and implications for research. Carcinogenesis 16:39–52 (1995).
444. Colvin ME, Hatch FT, Felton JS. Chemical and biological factors affecting mutagen potency. Mutat Res 400:479–492 (1998).
445. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 88:1442–1455 (1996).
446. Parshad R, Price FM, Bohr VA, Cowans KH, Zujewski JA, Sanford KK. Deficient DNA repair capacity, a predisposing factor in breast cancer. Br J Cancer 74:1–5 (1996).
447. Rao NM, Pai SA, Shinde SR, Ghosh SN. Reduced DNA repair capacity in breast cancer patients and unaffected individuals from breast cancer families. Cancer Genet Cytogenet 102:65–73 (1998).
448. Miki Y, Swensen J, Shattuckeidens D, Futreal PA, Harshman K, Tavtigian S, Liu QY, Cochran C, Bennett LM, Ding W, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66–71 (1994).
449. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G. Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789–792 (1995).
450. Bork P, Hofmann K, Bucher P, Neuwald AF, Altschul SF, Koonin EV. A superfamily of conserved domains in DNA damage responsive cell cycle checkpoint proteins. FASEB J 11:68–76 (1997).
451. Larson JS, Tonkinson JL, Lai MT. A *BRCA1* mutant alters G_2-M cell cycle control in human mammary epithelial cells. Cancer Res 57:3351–3355 (1997).
452. Scully R, Chen JJ, Ochs RL, Keegan K, Hoekstra M, Feunteun J, Livingston DM. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell 90:425–435 (1997).
453. Sharan SK, Morimatsu M, Albrecht U, Lim DS, Regel E, Dinh C, Sands A, Eichele G, Hasty P, Bradley A. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 386:804–810 (1997).
454. Somasundaram K, Zhang HB, Zeng YX, Houvras Y, Peng Y, Zhang HX, Wu GS, Licht JD, Weber BL, El-Deiry WS. Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor $p21^{WAF1/CIP1}$. Nature 389:187–190 (1997).
455. Thomas JE, Smith M, Tonkinson JL, Rubinfeld B, Polakis P. Induction of phosphorylation on BRCA1 during the cell cycle and after DNA damage. Cell. Growth Differ 8:801–809 (1997).
456. Zhang HB, Somasundaram K, Peng Y, Tian H, Zhang HX, Bi DK, Weber BL, El-Deiry WS. BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene 16:1713–1721 (1998).
457. Zhang HB, Tombline G, Weber BL. BRCA1, BRCA2, and DNA damage response: collision or collusion? Cell 92:433–436 (1998).
458. Aaltonen LA, Peltomaki P, Mecklin JP, Jarvinen H, Jass JR, Green JS, Lynch HT, Watson P, Tallqvist G, Juhola M, et al. Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res 54:1645–1648 (1994).
459. Risinger JI, Berchuck A, Kohler MF, Watson P, Lynch HT, Boyd J. Genetic instability of microsatellites in endometrial carcinoma. Cancer Res 53:5100–5103 (1993).
460. Loeb LA. Microsatellite instability: marker of a mutator phenotype in cancer. Cancer Res 54:5059–5063 (1994).
461. Umar A, Boyer JC, Thomas DC, Nguyen DC, Risinger JI, Boyd J, Ionov Y, Perucho M, Kunkel TA. Defective mismatch repair in extracts of colorectal and endometrial cancer cell lines exhibiting microsatellite instability. J Biol Chem 269:14367–14370 (1994).
462. Wei Q, Matanoski GM, Farmer ER, Hedayati MA, Grossman L. DNA repair related to multiple skin cancers and drug use. Cancer Res 54:437–440 (1994).
463. Boyer JC, Umar A, Risinger JI, Lipford JR, Kane M, Yin S, Barrett JC, Kolodner RD, Kunkel TA. Microsatellite instability, mismatch repair deficiency, and genetic defects in human cancer cell lines. Cancer Res 55:6063–6070 (1995).
464. Branch P, Hampson R, Karran P. DNA mismatch binding defects, DNA damage tolerance, and mutator phenotypes in human colorectal carcinoma cell lines. Cancer Res 55:2304–2309 (1995).
465. Fishel R, Kolodner RD. Identification of mismatch repair genes and their role in the development of cancer. Curr Opin Genet Dev 5:382–395 (1995).
466. Pandita TK, Hittelman WN. Evidence of a chromatin basis for increased mutagen sensitivity associated with multiple primary malignancies of the head and neck. Int J Cancer 61:738–743 (1995).
467. Eshleman JR, Markowitz SD. Mismatch repair defects in human carcinogenesis. Hum Mol Genet 5:1489–1494 (1996).
468. Wei Q, Cheng L, Hong WK, Spitz MR. Reduced DNA repair capacity in lung cancer patients. Cancer Res 56:4103–4107 (1996).
469. Li D, Wang M, Cheng L, Spitz MR, Hittelman WN, Wei Q. *In vitro* induction of benzo(a)pyrene diol epoxide-DNA adducts in peripheral lymphocytes as a susceptibility marker for human lung cancer. Cancer Res 56:3638–3641 (1996).
470. Chen WS, Chen JY, Liu JM, Lin WC, King KL, Whang Peng J, Yang WK. Microsatellite instability in sporadic-colon-cancer patients with and without liver metastases. Int J Cancer 74: 470–474 (1997).
471. Paz-y-Mino C, Penaherrera MS, Sanchez ME, Cordova A, Gutierrez S, Ocampo L, Leone PE. Comparative study of chromosome aberrations induced with aphidicolin in women affected by breast cancer and cervix uterine cancer. Cancer Genet Cytogenet. 94:120–124 (1997).
472. Wei Q, Bondy ML, Mao L, Gaun Y, Cheng L, Cunningham J, Fan Y, Bruner JM, Yung WK, Levin VA, Kyritsis AP. Reduced expression of mismatch repair genes measured by multiplex reverse transcription-polymerase chain reaction in human gliomas. Cancer Res 57:1673–1677 (1997).
473. Loeb LA. Cancer cells exhibit a mutator phenotype. Adv. Cancer Res. 72:25–56 (1998).
474. Karran P, Hampson R. Genomic instability and tolerance to alkylating agents. Cancer Surv 28:69–85 (1996).
475. Umar A, Kunkel TA. DNA-replication fidelity, mismatch repair and genome instability in cancer cells. Eur J Biochem 238:297–307 (1996).
476. Paulson TG, Wright FA, Parker BA, Russack V, Wahl GM. Microsatellite instability correlates with reduced survival and poor disease prognosis in breast cancer. Cancer Res 56:4021–4026 (1996).
477. Davis TW, Wilson-Van Patten C, Meyers M, Kunugi KA, Cuthill S, Reznikoff C, Garces C, Poland CR, Kinsella TJ, Fishel R, et al. Defective expression of the DNA mismatch repair protein, MLH1, alters G_2-M cell cycle checkpoint arrest following ionizing radiation. Cancer Res 58:767–778 (1998).
478. de Wind N, Dekker M, Berns A, Radman M, te Riele H. Inactivation of the mouse *Msh2* gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer. Cell 82:321–330 (1995).
479. Reitmair AH, Schmits R, Ewel A, Bapat B, Redston M, Mitri A, Waterhouse P, Mittrucker HW, Wakeham A, Liu B, et al. MSH2 deficient mice are viable and susceptible to lymphoid tumours. Nat Genet 11:64–70 (1995).
480. Baker SM, Harris AC, Tsao JL, Flath TJ, Bronner CE, Gordon M, Shibata D, Liskay RM. Enhanced intestinal adenomatous polyp formation in *Pms2*$^{-/-}$;*Min* mice. Cancer Res 58:1087–1089 (1998).
481. Prolla TA, Baker SM, Harris AC, Tsao J-L, Yao X, Bronner CE, Zheng B, Gordon M, Reneker J, Arnheim N, et al. Tumour susceptibility and spontaneous mutation in mice deficient in *Mlh1, Pms1* and *Pms2* DNA mismatch repair. Nat Genet 18:276–279 (1998).
482. Jackson SP. The recognition of DNA damage. Curr Opin Genet Dev 6:19–25 (1996).
483. Kaufmann WK, Paules RS. DNA damage and cell cycle checkpoints. FASEB J 10:238–247 (1996).
484. Donehower LA. Genetic instability in animal tumorigenesis models. Cancer Surv 29:329–352 (1997).
485. Harley CB, Sherwood SW. Telomerase, checkpoints and cancer. Cancer Surv 29:263–284 (1997).
486. Lengauer C, Kinzler KW, Vogelstein B. DNA methylation and genetic instability in colorectal cancer cells [see comments]. Proc Natl Acad Sci USA 94:2545–2550 (1997).
487. Kaufmann WK. Human topoisomerase II function, tyrosine phosphorylation and cell cycle checkpoints. Proc Soc Exp Biol Med 217:327–334 (1998).
488. Heppner GH, Miller FR. The cellular basis of tumor progression. Int Rev Cytol 177:1–56 (1998).
489. Tennant RW. A perspective on nonmutagenic mechanisms in carcinogenesis. Environ Health Perspect 3:231–236 (1993).
490. Mortelmans K, Haworth S, Lawlor T, Speck W, Tainer B, Zeiger E. Salmonella mutagenicity tests. II: Results from the testing of 270 chemicals. Environ Mutagen 7:1–119 (1986).